Tivity Health (TVTY) 10-K 25 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 17, 2022	Jun. 30, 2021
Cover [Abstract]
Entity Registrant Name	TIVITY HEALTH, INC.
Entity Central Index Key	0000704415
Current Fiscal Year End Date	--12-31
Trading Symbol	TVTY
Title of 12(b) Security	Common Stock - $.001 par value
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1.2
Entity Common Stock, Shares Outstanding		49,823,312
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-19364
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	62-1117144
Entity Address, Address Line One	701 Cool Springs Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	800
Local Phone Number	869-5311
ICFR Auditor Attestation Flag	true
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Nashville, Tennessee
Documents Incorporated by Reference	Portions of the registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 60,132	$ 100,385
Accounts receivable, net	62,730	25,981
Prepaid expenses	6,465	5,556
Income taxes receivable	3,095	10,996
Investment in equity securities	49,746
Other current assets	13,733	11,336
Total current assets	195,901	154,254
Property and equipment, net of accumulated depreciation of $44,229 and $38,188 respectively	25,247	20,959
Right-of-use assets	10,695	18,139
Long-term deferred tax asset		3,601
Intangible assets, net	29,049	29,049
Goodwill, net	334,680	334,680
Investment in equity securities, long-term		10,773
Other assets	2,969	7,528
Total assets	598,541	578,983
Current liabilities:
Accounts payable	25,325	19,741
Accrued salaries and benefits	11,825	8,949
Accrued liabilities	28,270	18,424
Deferred revenue	3,371	4,460
Current portion of long-term debt		7,456
Current portion of lease liabilities	8,007	8,052
Current portion of other long-term liabilities	10,625	14,753
Total current liabilities	87,423	81,835
Long-term debt	380,504	459,250
Long-term lease liabilities	3,487	11,494
Long-term deferred tax liability	3,183
Other long-term liabilities	5,037	22,748
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding
Common Stock $.001 par value, 120,000,000 shares authorized, 49,800,756 and 48,983,735 shares outstanding, respectively	50	49
Additional paid-in capital	514,461	513,263
Accumulated deficit	(359,171)	(464,085)
Treasury stock, at cost, 2,254,953 shares in treasury	(28,182)	(28,182)
Accumulated other comprehensive loss	(8,251)	(17,389)
Total stockholders' equity	118,907	3,656
Total liabilities and stockholders' equity	$ 598,541	$ 578,983

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accumulated depreciation	$ 44,229	$ 38,188
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	49,800,756	48,983,735
Treasury stock (in shares)	2,254,953	2,254,953

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues		$ 481,252	$ 437,714	$ 633,066
Cost of revenue (exclusive of depreciation of $10,662, $9,209, and $5,920, respectively, included below)		278,252	250,362	445,817
Marketing expense		6,529	12,197	17,720
Selling, general and administrative expenses		41,991	42,765	53,198
Depreciation expense		11,298	9,930	7,137
Restructuring and related charges			4,358	1,881
Operating income		143,182	118,102	107,313
Interest expense		34,762	43,477	41,803
Loss on extinguishment and modification of debt		19,027
Other (income) expense, net		(44,328)	226
Total non-operating expense, net		9,461	43,703	41,803
Income before income taxes		133,721	74,399	65,510
Income tax expense		26,345	17,530	20,293
Income from continuing operations		107,376	56,869	45,217
Loss from discontinued operations, net of income tax benefit of $844, $46,851, and $59,881, respectively		(2,462)	(280,500)	(332,038)
Net income (loss)		$ 104,914	$ (223,631)	$ (286,821)
Earnings (loss) per share - basic:
Continuing operations		$ 2.17	$ 1.17	$ 0.97
Discontinued operations		(0.05)	(5.75)	(7.14)
Net income (loss)	[1]	2.12	(4.59)	(6.17)
Earnings (loss) per share – diluted:
Continuing operations		2.13	1.16	0.96
Discontinued operations		(0.05)	(5.70)	(7.05)
Net income (loss)		$ 2.08	$ (4.54)	$ (6.09)
Comprehensive income (loss)		$ 114,052	$ (228,929)	$ (298,912)
Weighted average common shares and equivalents:
Basic		49,573	48,746	46,509
Diluted		50,424	49,217	47,103
[1]	Figures may not add due to rounding.

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Depreciation	$ 10,662	$ 9,209	$ 5,920
Discontinued operation, income tax (benefit)	$ 844	$ 46,851	$ 59,881

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 104,914	$ (223,631)	$ (286,821)
Net change in fair value of effective portion of interest rate swaps designated as cash flow hedges, net of tax (expense) benefit of ($2,981), $5,540, and $4,147, respectively	8,691	(16,151)	(12,091)
Reclassification adjustment for loss from interest rate swaps de- designated as cash flow hedges included in "Loss from discontinued operations, net," net of tax of $3,661		10,675
Reclassification adjustment for previously deferred loss from interest rate swaps included in "Interest expense," net of tax of $153 and $61, respectively	447	178
Total other comprehensive income (loss), net of tax	9,138	(5,298)	(12,091)
Comprehensive income (loss)	$ 114,052	$ (228,929)	$ (298,912)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net change in fair value of effective portion of interest rate swaps designated as cash flow hedges, tax (expense) benefit	$ (2,981)	$ 5,540	$ 4,147
Reclassification adjustment for loss from interest rate swaps de-designated as cash flow hedges, tax		3,661
Reclassification adjustment for previously deferred loss from interest rate swaps, tax	$ 153	$ 61

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2018	$ 365,791	$ 41	$ 347,487	$ 46,445	$ (28,182)
Comprehensive income (loss)	(298,912)			(286,821)		$ (12,091)
Issuance of Common Stock in connection with Merger	132,838	6	132,832
Share-based compensation replacement awards related to merger and attributable to pre-combination services	9,107		9,107
Exercise and vesting of share-based compensation awards	989	1	988
Tax withholding for share-based compensation	(4,733)		(4,733)
Share-based employee compensation expense	18,832		18,832
Other	(212)		(94)	(118)
Balance at Dec. 31, 2019	223,700	48	504,419	(240,494)	(28,182)	(12,091)
Comprehensive income (loss)	(228,929)			(223,631)		(5,298)
Exercise and vesting of share-based compensation awards	1,025	1	1,024
Tax withholding for share-based compensation	(6,257)		(6,257)
Share-based employee compensation expense	14,077		14,077
Other	40			40
Balance at Dec. 31, 2020	3,656	49	513,263	(464,085)	(28,182)	(17,389)
Comprehensive income (loss)	114,052			104,914		9,138
Exercise and vesting of share-based compensation awards	686	1	685
Tax withholding for share-based compensation	(8,796)		(8,796)
Share-based employee compensation expense	10,060		10,060
Repurchases of common stock	(751)		(751)
Balance at Dec. 31, 2021	$ 118,907	$ 50	$ 514,461	$ (359,171)	$ (28,182)	$ (8,251)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Income (loss) from continuing operations	$ 107,376	$ 56,869	$ 45,217
Loss from discontinued operations	(2,462)	(280,500)	(332,038)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Loss on extinguishment of debt	18,237
Depreciation and amortization	11,298	45,887	50,775
Amortization and write-off of deferred loan costs	2,973	9,190	4,487
Amortization and write-off of debt discount	1,861	8,604	3,711
Share-based employee compensation expense	10,060	14,077	18,832
(Gain) loss on derivatives	(2,627)	14,562
Unrealized gain on investments in equity securities	(39,232)
Realized gain on investments in equity securities	(2,469)
Impairment of goodwill and intangible assets of discontinued operation		199,500	377,100
Loss on sale of Nutrition business		90,163
Deferred income taxes	3,649	(38,438)	(52,076)
(Increase) decrease in accounts receivable, net	(36,749)	63,239	(8,283)
Changes in income taxes receivable and payable	7,901	(11,401)	1,125
(Increase) decrease in other current assets	(1,549)	12,125	941
Decrease in accounts payable	(951)	(3,182)	(10,052)
Increase in accrued salaries and benefits	2,876	128	3,608
Increase (decrease) in other current liabilities	5,342	(18,765)	(21,900)
(Decrease) increase in deferred revenue	(1,089)	686	(1,198)
Other	2,678	6,703	2,056
Net cash flows provided by operating activities	87,123	169,447	82,305
Cash flows from investing activities:
Acquisition of property and equipment	(14,750)	(15,525)	(24,713)
Proceeds from sale of Nutrition business, net of cash transferred	2,747	558,067
Proceeds from sale of equity securities	2,728
Settlement on derivatives not designated as hedges	(6,697)	(1,499)
Business acquisitions, net of cash acquired			(1,062,818)
Net cash flows provided by (used in) investing activities	(15,972)	541,043	(1,087,531)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	398,000	196,525	1,611,970
Payments of long-term debt	(502,275)	(795,100)	(574,329)
Deferred loan costs	(3,953)		(30,189)
Payments related to tax withholding for share-based compensation	(8,796)	(6,257)	(4,733)
Proceeds from exercise of stock options	686	1,025	989
Repurchases of common stock	(751)
Change in cash overdraft and other	5,685	(8,784)	2,083
Net cash flows provided by (used in) financing activities	(111,404)	(612,591)	1,005,791
Effect of exchange rate changes on cash			(12)
Net increase (decrease) in cash and cash equivalents	(40,253)	97,899	553
Cash and cash equivalents, beginning of period	100,385	2,486	1,933
Cash and cash equivalents, end of period	60,132	100,385	2,486
Supplemental disclosure of cash flow information:
Cash paid for interest	29,465	71,439	67,717
Cash paid for income taxes, net of refunds	$ 13,951	$ 20,433	$ 8,370

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Tivity Health, Inc. (the “Company”) was founded and incorporated in Delaware in 1981. We are a leading provider of healthy life-changing solutions, including SilverSneakers ® ® TM We deliver resources that enable members to live healthier, happier, more connected lives. Our solutions support health plans and employers nationwide as they seek to reduce costs and improve health outcomes. Effective as of December 9, 2020, we completed the sale of Nutrisystem. Results of operations for Nutrisystem have been classified as discontinued operations for all periods presented in the consolidated financial statements. Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health, Inc. and its wholly owned subsidiaries (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement. We have reclassified certain items in prior periods to conform to current classifications. a. Principles of Consolidation – See discussion above regarding Nutrisystem. We have eliminated all intercompany profits, transactions, and balances. b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit. Book cash overdrafts issued, but not yet presented to the bank for payment, are reclassified to accounts payable. c. Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed or products sold, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2021 and 2020. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables were $16.2 million and $5.7 million at December 31, 2021 and 2020, respectively, and d. Investment in equity securities – At December 31, 2021, investment in equity securities consists of 11,079,331 shares of common stock of Sharecare, Inc. As required under Accounting Standard Codification (“ASC”) 321, beginning in July 2021, we carry the investment at fair value and recognize any changes in fair value in net income as unrealized gains or losses. See Note 12 for further information on investment in equity securities. e. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and office equipment, and three to five years for equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense, including depreciation of assets recorded under finance leases, for the years ended December 31, 2021, 2020, and 2019 was $11.3 million, $9.9 million, and $7.1 million, respectively. f . Leases – We recognize right-of-use assets and lease liabilities for leases with contractual terms longer than twelve months, and we categorize such leases as either operating or finance. Finance leases are generally those leases that allow us to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. Our leases generally have remaining lease terms of seven to 33 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the asset or liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative fair values. Lease liabilities are recognized at the present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the leases. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Costs associated with right-of-use assets are recognized on a straight-line basis within operating expenses over the term of the lease. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. See Note 9 for further information on leases. g . Intangible Assets - Intangible assets subject to amortization include acquired technology and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets related to continuing operations and subject to amortization were fully amortized at December 31, 2021 and 2020. Intangible assets related to continuing operations and not subject to amortization at December 31, 2021 and 2020 consist of a trade name of $29.0 million. In accordance with ASC 350, we review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. See Note 6 for further information on intangible assets. h . Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. In accordance with ASC 350, we review g o odwill for i mp airm e nt at the rep o rting unit lev e l (op e rat i ng s e gment o r one level b e low an o perating s e gmen t ) on an a n nual bas i s ( d ur i ng the fourth q u arter of o u r fiscal year) or more frequ en t ly whenever events or circumsta n c e s i n dicate that th e carryin g v a lu e ma y no t b e r e cov e rab l e . Following the sale of our Nutrition business in December 2020, we have a single As part of the annual impairment test o e m n i o a n w i i o a n i . Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank. j . Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to fitness network locations (which actual visit data is typically received approximately one month in arrears) k . Income Taxes - We file a consolidated federal income tax return that includes all of our wholly owned subsidiaries. U.S. GAAP generally requires that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income. l . Revenue Recognition - See Note 4 for a further discussion of revenue recognition. m . Marketing Expense – Marketing expense includes media, advertising production, marketing, and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense from continuing operations was $4.0 million, $7.2 million, and $7.1 million in 2021, 2020, and 2019, respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on a cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or, in the case of production costs, the first time the advertising takes place. At December 31, 2021 and 2020, $1.8 million and $0 million, respectively, of costs have been prepaid for future advertisements and promotions. n . Earnings (Loss) Per Share – We calculate basic earnings (loss) per share using weighted average common shares outstanding during the period. We calculate diluted earnings (loss) per share using weighted average common shares outstanding during the period plus the effect of all dilutive potential common shares outstanding during the period unless the impact would be anti-dilutive. During 2019 and 2020, we used the two-class method to calculate earnings per share (“EPS”) as the unvested restricted stock awards outstanding under our equity incentive plan were participating shares with nonforfeitable rights to dividends. Under the two-class method, we computed earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period. In applying the two-class method, we allocated undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect was given to the participating securities because they did not share in the losses of the Company. There were no participating securities during 2021; as such, we did not calculate EPS using the two-class method during 2021. See o . Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 7 for a further discussion of share-based compensation. p . Derivative Instruments and Hedging Activities – We generally use derivative instruments to add stability to interest expense and to manage our exposure to interest rate movements. We account for derivatives in accordance with Financial Accounting Standards Board (“FASB”) ASC Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. For derivatives that are designated and qualify as effective cash flow hedges, the unrealized gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings as interest expense when the hedged transaction affects earnings. If a derivative instrument ceases to be a highly effective hedge, we will discontinue hedge accounting prospectively for the affected derivative instrument. The application of the authoritative guidance could impact the volatility of earnings. See Note 14 for further information on derivative instruments and hedging activities. q . Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	2 . Discontinued Operations Effective as of December 9, 2020, we completed the sale of Nutrisystem, Inc. (“Nutrisystem”) to KNS Acquisition Corp. (“Kainos”) for Such working capital adjustment was finalized in the second quarter of 2021 and resulted in additional proceeds of $2.7 million. Additionally, we incurred $11.2 million of transaction costs in 2020 directly related to the disposition of Nutrisystem, resulting in net proceeds, after post-closing adjustment, of $550.4 million. In accordance with ASC Topic 205, “Presentation of Financial Statements”, the Nutrition business met the criteria for discontinued operations, as it was a component of the Company and the sale represented a strategic shift in the Company’s operations and financial results. Accordingly, the results of operations of the Nutrition business have been classified as discontinued operations for 2019, 2020, and 2021. The following table presents financial results of the Nutrition business included in “loss from discontinued operations" for the years ended December 31, 2021, 2020 and 2019. Year Ended December 31 (In thousands) 2021 2020 (1) 2019 (2) Revenues $ — $ 617,191 $ 498,091 Cost of revenues — 291,097 232,240 Marketing expenses — 196,952 140,286 Selling, general and administrative expenses (3) 3,210 59,093 56,840 Depreciation and amortization — 35,957 43,638 Impairment loss — 199,500 377,100 Restructuring and related charges — 472 5,143 Interest expense (4) — 36,798 34,763 Pretax loss from discontinued operations (3,210 ) (202,678 ) (391,919 ) Loss on de-designation of cash flow hedges (5) — (14,336 ) — Write-off of deferred loan costs and debt discount (4) — (8,946 ) — Loss on sale of Nutrition business (6) (96 ) (101,391 ) — Total pretax loss from discontinued operations $ (3,306 ) $ (327,351 ) $ (391,919 ) Income tax benefit (844 ) (46,851 ) (59,881 ) Loss from discontinued operations, net of income tax benefit $ (2,462 ) $ (280,500 ) $ (332,038 ) (1) (2) (3) (4) The term loans under our Prior Credit Agreement (as defined in Note 10) were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Prior Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates. (5) (6) For the year ended December 31, 2020, the loss on sale of business consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 13), which includes post-closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem . During the year ended December 31, 2021, an additional loss of $ 0.1 million was recognized upon final settlement of the post- c losing working capital adjustment. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31 (In thousands) 2021 2020 2019 Impairment of goodwill and intangible assets $ — $ 199,500 $ 377,100 Loss on sale of business — 90,163 — Depreciation and amortization — 35,957 43,638 Loss on de-designation of cash flow hedges — 14,336 — Write-off of deferred loan costs and debt discount (1) — 8,946 — Capital expenditures on discontinued operations — 6,794 10,168 Share-based compensation on discontinued operations — 4,351 13,230 Deferred income taxes (844 ) (54,561 ) (68,488 ) (1) Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Recent Relevant Accounting Stan

Recent Relevant Accounting Standards	12 Months Ended
	Dec. 31, 2021
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Relevant Accounting Standards	3 . Re c o a d In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of December 31, 2021, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows . In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “ Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. In January 2021, the FASB issued ASU 2021-01, “Reference Rate Reform: Scope”, which refines the scope of ASC 848 and clarifies the application of its guidance. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue Recognition	4. Revenue Recognition We account for revenue from contracts with customers in accordance with ASC Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied. We earn revenue from continuing operations primarily from three programs: SilverSneakers senior fitness, Prime Fitness, and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage, Medicare Supplement, and group retiree plans through our contracts with such plans. We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans. Except for Prime Fitness, our customer contracts generally have initial terms of approximately three years. Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs. For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while i . The significant majority of customer contracts contain one Deferred revenue was $3.4 million and $4.5 million at December 31, 2021 and 2020, respectively. During 2021, we recognized $4.4 million of revenue that was included in deferred revenue at December 31, 2020 and increased deferred revenue by $3.3 million, excluding amounts recognized as revenue during 2021. Our fees are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. Due to the COVID-19 pandemic, t he average monthly total participation levels of our members have fluctuated significantly since March 2020. For the year ended December 31, 2021, total SilverSneakers visits and revenues were higher than the same period in 2020 as the effects of the COVID-19 pandemic lessened compared to the prior year period. As a result, revenues from PMPM fees (which are not derived from visits) represented 47% of SilverSneakers revenue for the year ended December 31, 2021, compared to 54% for the year ended December 31, 2020. Our customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient. Although we evaluate our financial performance and make resource allocation decisions based upon the results of our single The following table sets forth revenue from continuing operations disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Year Ended December 31 2021 2020 2019 SilverSneakers $ 362,767 $ 313,575 $ 492,778 Prime Fitness 94,254 95,015 120,949 WholeHealth Living 23,777 19,776 18,511 Other (1) 454 9,348 828 $ 481,252 $ 437,714 $ 633,066 (1) For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million of revenue from home-delivered meals. Sales and usage-based taxes are excluded from revenues.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment	5 . Property and Equipment Property and equipment at December 31, 2021 and 2020 consisted of the following: (In thousands) December 31, 2021 December 31, 2020 Leasehold improvements $ 7,627 $ 7,963 Computer equipment and related software 57,095 45,504 Furniture and office equipment 2,683 4,418 Capital projects in process 2,071 1,262 Total property and equipment at cost $ 69,476 $ 59,147 Less: accumulated depreciation (44,229 ) (38,188 ) Total property and equipment, net $ 25,247 $ 20,959

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	6 . Intangible Assets and Goo d w i ll There was no c h g the m d of continuing operations i r n e b 31 2021 or 2020. Intangible assets subject to amortization at December 31, 2021 and 2020 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ — As all intangible assets subject to amortization were fully amortized as of December 31, 2016, no amortization was incurred during the years ended December 31, 2021, 2020, and 2019, and no amortization expense is expected over the next five years and thereafter. At December 31, 2021 and 2020, intangible assets not subject to amortization consisted of a tradename of

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	7 . Share-Based Compensation During 2021 we had h e a e d a d oc n performance-based stock units, and market stock units h ba a a d a e o l e e o o c l We grant options under our stock incentive plan at fair value on the date of grant. The options generally vest over or at the end of three years based on service conditions and expire seven or ten years from the date of grant. Restricted stock units generally vest over three or four years. Performance-based stock units had a multi-year performance period and vested approximately two or three years from the grant date. Market stock units granted during 2020 have a three-year We recognize share-based compensation expense for options, restricted stock units, and performance-based stock units on a straight-line basis over the vesting period. We account for forfeitures as they occur. We recognize share-based compensation expense for market stock units if the requisite service period is rendered, even if the market condition is never satisfied. All awards generally provide for accelerated vesting upon a change in control or normal or early retirement (as defined in the applicable equity award agreement or stock incentive plan). At December 31, 2021, we had reserved approximately 1.1 million shares for future equity grants under our stock incentive plans. Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2021, 2020, and 2019. We did not capitalize any share-based compensation costs during these periods. Year Ended December December December 31, (In millions) 2021 2020 2019 Share-based compensation included in cost of revenue $ 2.5 $ 2.7 $ 2.2 Share-based compensation included in selling, general and administrative expenses 7.6 6.2 3.4 Share-based compensation included in restructuring and related charges — 0.8 — Share-based compensation included in continuing operations $ 10.1 $ 9.7 $ 5.6 Share-based compensation included in discontinued operations — 4.4 13.2 Total share-based compensation $ 10.1 $ 14.1 $ 18.8 Total income tax benefit recognized in continuing operations 2.6 2.5 1.4 As of December 31, 2021, there was $10.2 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under our stock incentive plan. That total cost is expected to be recognized over a weighted average period of 1.4 years. Stock Options We use a lattice-based binomial option valuation model ("lattice binomial model") to estimate the fair values of stock options. We base expected volatility on historical volatility due to the low volume of traded options on our stock. The expected term of options granted is derived from the output of the lattice binomial model and represents the period of time that options granted are expected to be outstanding. We used historical data to estimate expected option exercise and post-vesting employment termination behavior within the lattice binomial model. The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the years ended December 31, 2021 and 2020. There were no stock options granted during fiscal 2019. Year Ended December 2021 Year Ended December 2020 Year Ended December 2019 Weighted average grant-date fair value of options per share $ 13.31 $ 8.20 $ — Expected term (in years) 6.3 6.2 — Assumptions: Expected volatility 63.1 % 63.2 % — Expected dividends — — — Risk-free rate 1.4 % 0.7 % — A summary of options as of December 31, 2021 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (In years) Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2021 422 $ 17.83 Granted 178 26.48 Exercised (81 ) 12.47 Forfeited (24 ) 17.64 Expired (2 ) 35.82 Outstanding at December 31, 2021 493 $ 21.75 5.4 $ 2,805 Exercisable at December 31, 2021 122 $ 22.82 3.4 $ 906 The total intrinsic value, which represents the difference between the market price of the underlying common stock and the option's exercise price, of options exercised during the years ended December 31, 2021, 2020, and 2019 was $0.9 million, $0.6 million, and $0.6 million, respectively. Cash received from option exercises under all share-based payment arrangements during 2021 was $0.7 million. The actual tax benefit realized during 2021 for the tax deductions from option exercises totaled $0.2 million. We issue new shares of common stock upon exercise of stock options or vesting of restricted stock units, restricted stock awards, performance-based stock units, and market stock units. Nonvested Shares The fair value of restricted stock units and performance-based stock units is determined based on the closing bid price of the Company's common stock on the grant date. The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2021, 2020, and 2019 was $24.15, $11.17, and $19.68, respectively. The weighted average grant-date fair value of performance-based stock units granted during the years ended December 31, 2020 and 2019 was $21.49 and $20.20, respectively. No performance-based stock units were granted during 2021. The three tables below set forth a summary of our nonvested shares as of December 31, 2021, as well as activity during the year then ended. The total grant-date fair value of shares vested during the years ended December 31, 2021, 2020, and 2019 was $10.9 million, $13.6 million, and $23.5 million, respectively. Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 1,241 $ 11.58 Granted 164 24.15 Vested (803 ) 11.43 Forfeited (21 ) 15.48 Nonvested at December 31, 2021 581 $ 15.20 Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 86 $ 20.30 Vested (84 ) 20.31 Forfeited (2 ) 19.71 Nonvested at December 31, 2021 — $ — Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 150 $ 18.84 Nonvested at December 31, 2021 150 $ 18.84

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	8 . Income Taxes Income tax expense is comprised of the following: Year Ended December 31, (In thousands) 2021 2020 2019 Current taxes: Federal $ 16,421 $ 526 $ 3,051 State 5,431 881 830 Deferred taxes: Federal 5,658 14,114 11,853 State (1,165 ) 2,009 4,559 Total $ 26,345 $ 17,530 $ 20,293 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table sets forth the significant components of our net deferred tax liability and asset as of December 31, 2021 and 2020: (In thousands) December 31, 2021 December 31, 2020 Deferred tax asset: Accruals and reserves $ 467 $ 1,137 Deferred compensation 169 604 Share-based payments 1,279 2,909 Lease liability 2,936 4,993 Section 163(j) interest limitation 2,902 370 Interest rate swap 2,830 5,964 Unrealized losses — 3,720 Net operating loss carryforwards 19,962 10,608 Capital loss carryforwards 145,330 149,608 175,875 179,913 Valuation allowance (148,754 ) (152,295 ) $ 27,121 $ 27,618 Deferred tax liability: Property and equipment $ (5,614 ) $ (4,516 ) Intangible assets (14,986 ) (14,868 ) Unrealized gains (6,972 ) — Right-of-use assets (2,732 ) (4,633 ) (30,304 ) (24,017 ) Net long-term deferred tax (liability) asset $ (3,183 ) $ 3,601 At December 31, 2021, we provided a total valuation allowance of $148.8 million, which consisted of (i) $2.4 million of deferred tax assets associated with our international net operating loss carryforwards, (ii) $11.0 million of deferred tax assets associated with our state net operating loss carryforwards, and (iii) $135.4 million for deferred tax assets related to capital loss carryforwards generated in the 2020 sale of Nutrisystem. Capital loss carryforwards can only be used to offset future capital gains and cannot be used to offset any future operating losses the Company may incur. We reduced our valuation allowance at December 31, 2021 by $9.9 million based on the positive evidence provided by the $39.2 million unrecognized capital gain in our equity ownership in Sharecare. We recorded a total decrease in our valuation allowance of $3.5 million for the year ended December 31, 2021. Our valuation allowance at December 31, 2020 totaled $152.3 million. At December 31, 2021, we had international net operating loss carryforwards totaling approximately $8.3 million, $8.0 million of which have an indefinite carryforward period, approximately $344.1 million of state net operating loss carryforwards expiring between 2026 and 2040, and approximately $573.4 million of capital loss carryforwards expiring in 2025. We recorded a tax effect of $2.8 million in 2021 related to our interest rate swap agreements to stockholder’s equity as a component of accumulated other comprehensive income (loss). The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2021 2020 2019 Statutory federal income tax $ 28,081 $ 15,624 $ 13,757 State income taxes, less federal income tax benefit 6,675 3,607 3,048 Executive compensation 2,172 1,062 150 Change in valuation allowance (14,275 ) (2,659 ) 2,509 Share-based compensation (2,644 ) 426 210 State income tax credits — — 954 Capital loss expiration 7,139 — — Prior year tax adjustments (970 ) (592 ) (464 ) Net impact of foreign operations 69 3 (9 ) Other 98 59 138 Income tax expense $ 26,345 $ 17,530 $ 20,293 Uncertain Tax Positions As of December 31, 2021, we had no unrecognized tax benefits that would affect our effective tax rate. During 2020, we recorded a $1.1 million decrease to unrecognized tax benefits primarily related to the unrecognized tax benefits divested in the sale of Nutrisystem. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows. There were no changes in unrecognized tax benefits during 2021. (In thousands) Unrecognized tax benefits at December 31, 2019 $ 1,061 Increases related to prior year tax positions 84 Decreases due to lapse of statute of limitations (20 ) Decreases related to Nutrisystem divestiture (1,125 ) Unrecognized tax benefits at December 31, 2020 $ — We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions. Tax years remaining subject to examination in the U.S. Federal jurisdiction include 2018 to present.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	9 . Leases We account for leases under ASC 842. We maintain lease agreements principally for our office spaces and certain equipment. We maintain two sublease agreements with respect to one of our office locations, each of which continues through the initial term of our master lease agreement. Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability. With the exception of two finance leases related to a network server and office equipment, all of our leases are classified as operating leases. In the aggregate, our leases generally have remaining lease terms of seven to 33 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the right-of-use asset or lease liability because it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative standalone selling prices. Upon adoption of ASC 842, we determined our estimated discount rate for existing leases as of January 1, 2019 based on the incremental borrowing rate that most closely aligned with the remaining lease term and payment schedule, as provided by our financial institution. The discount rates for leases entered into after January 1, 2019 were determined based on similarly secured borrowings available to us as of lease inception. The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: December 31, 2021 December 31, 2020 (In thousands) Right-of-use assets: Operating $ 10,327 $ 17,145 Finance 368 994 Total leased assets $ 10,695 $ 18,139 Lease liabilities: Current Operating $ 7,610 $ 7,408 Finance 397 644 Non-current Operating $ 3,487 $ 11,097 Finance - 397 Total lease liabilities $ 11,494 $ 19,546 The following table shows the components of lease expense: Year Ended December 31, Year Ended December 31, (In thousands) 2021 2020 Finance lease cost: Amortization of leased assets $ 626 $ 686 Interest of lease liabilities 42 86 Operating lease cost 7,578 7,872 Total lease cost before subleases $ 8,246 $ 8,644 Sublease income (5,377 ) (5,452 ) Total lease cost, net $ 2,869 $ 3,192 The following provides information related to the lease term and discount rate as of December 31, 2021: Weighted Average Remaining Lease Term (years) Operating leases 1.7 Finance leases 0.6 Weighted Average Discount Rate Operating leases 4.9 % Finance leases 5.9 % As of December 31 aturities of lease liabilities for each of the next five years and thereafter were as follows: Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases 2022 7,957 (5,732 ) 2,225 403 2023 2,518 (957 ) 1,561 — 2024 1,083 — 1,083 — Total lease payments 11,558 $ (6,689 ) $ 4,869 403 Less: interest (461 ) (6 ) Present value of lease liabilities $ 11,097 $ 397 Supplemental cash flow information related to leases was as follows: Year Ended December 31, Year Ended December 31, (In thousands) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (3,921 ) $ (3,492 ) Operating cash flow attributable to finance leases (42 ) (86 ) Financing cash flow attributable to finance leases (642 ) (622 ) For the years ended December 31, 2021 and 2020, there were no noncash transactions related to leases.

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	10 . Debt The Company’s debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at December 31, 2021 and 2020 was as follows: (In thousands) December 31, 2021 December 31, 2020 Term Loan A $ — $ 124,035 Term Loan B 394,000 372,240 394,000 496,275 Less: deferred loan costs and original issue discount (13,496 ) (29,569 ) Total debt 380,504 466,706 Less: current portion — (7,456 ) Total long-term debt $ 380,504 $ 459,250 Credit Facility On June 30, 2021, we entered into a new Credit Agreement (the “Credit Agreement”) with a group of lenders, Morgan Stanley Senior Funding, Inc., as general administrative agent, term loan facility administrative agent and collateral agent (“Morgan Stanley”), and Truist Bank, as revolving facility agent and swingline lender (“Truist”). The Credit Agreement replaced our prior Credit and Guaranty Agreement, dated March 8, 2019 (the “Prior Credit Agreement”), with a group of lenders, Credit Suisse AG, Cayman Islands Branch, as general administrative agent, term facility agent and collateral agent, and Truist, as revolving facility agent and swingline lender. The Credit Agreement provides us with (i) a $400.0 million term loan B facility (the “Term Loan B”), (ii) a $100.0 million revolving credit facility that includes a $30.0 million sublimit for swingline loans and a $40.0 million sublimit for letters of credit (the “Revolving Credit Facility”), and (iii) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $167.5 million or 100% of our Consolidated EBITDA (as defined in the Credit Agreement) for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements. As of December 31, 2021, outstanding debt under the Credit Agreement was $380.5 million, and availability under the revolving credit facility totaled $99.5 million as calculated under the most restrictive covenant. Upon execution of the Credit Agreement, we recorded a loss on extinguishment of debt of $18.2 million, which related to the write-off of certain unamortized original issue discount and deferred loan costs associated with the Prior Credit Agreement. Additionally, we incurred third-party costs of $0.8 million related to the execution of the Credit Agreement and the transactions that are the subject thereof, which were recorded as loss on modification of debt. We used the proceeds of the Term Loan B and cash on hand to repay all of the outstanding indebtedness under the Prior Credit Agreement, and to pay transaction costs and expenses. Proceeds of the Revolving Credit Facility also may be used for general corporate purposes of the Company and its subsidiaries. We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.25% of the aggregate initial amount of such loans, payable on September 30, 2021 and on the last day of each succeeding quarter thereafter until maturity on June 30, 2028, at which time the entire outstanding principal balance of such loans is due and payable in full. We are permitted to make voluntary prepayments of borrowings under the Term Loan B at any time without penalty, except for a 1% premium with respect to the principal of Term Loan B loans prepaid within six months after the date of the Credit Agreement using proceeds from certain specified repricing transactions. In October 2021, we made voluntary prepayments of $5.0 million on the Term Loan B, which prepaid all scheduled quarterly installments due through December 31, 2022. We are required to repay in full any outstanding swingline loans and revolving loans, and to terminate or cash collateralize any outstanding letters of credit, under the Revolving Credit Facility on June 30, 2026. In addition, the Credit Agreement contains provisions that, beginning with fiscal year 2022, may require annual exce Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, three-month or six-month LIBOR (or, if available to all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than 0.00%, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The Base Rate may not be less than 1.00%. The LIBOR margin for Term Loan B loans is 4.25%, and the LIBOR margin for revolving loans varies between 4.25% and 3.75% depending on our First Lien Net Leverage Ratio (as defined in the Credit Agreement). The Base Rate margin for Term Loan B loans is 3.25%, and the Base Rate margin for revolving loans varies between 3.25% and 2.75%, depending on our First Lien Net Leverage Ratio. Based on the Company’s elections, borrowings under the Prior Credit Agreement bore interest at variable rates based on a margin or spread in excess of one-month LIBOR, which could not be less than zero. The LIBOR margin for Term Loan A loans was 4.25%, the LIBOR margin for Term Loan B loans was 5.25%, and the LIBOR margin for revolving loans varied between 3.75% and 4.25%, depending on our total Net Leverage Ratio, as defined in the Prior Credit Agreement. In May 2019, we entered into eight amortizing interest rate swap agreements, each of which matures in May 2024. Under these interest rate swap agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2%. As further explained in Note 14, during the fourth quarter of 2020 we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we de-designated these derivatives. As of December 31, 2021, the eight interest rate swap agreements had current notional amounts totaling $600.0 million, of which $333.3 million related to effective hedges. The following table shows the effective interest rates related to continuing operations for Term Loan A and Term Loan B (exclusive of payments related to de-designated interest rate swaps, which we do not classify as interest expense) for the years ended December 31, 2021 and 2020: For the Year Ended December 31, Effective interest rate per annum 2021 2020 Term Loan A under the Prior Credit Agreement 6.58 % 6.64 % Term Loan B under the Prior Credit Agreement 7.22 % 7.08 % Term Loan B under the Credit Agreement 6.52 % — The Credit Agreement also provides for annual commitment fees ranging between 0.250% and 0.375% of the unused commitments under the Revolving Credit Facility, depending on our Total Net Leverage Ratio (as defined in the Credit Agreement), and annual letter of credit fees on the daily maximum amount available under outstanding letters of credit at the LIBOR margin for the Revolving Credit Facility. The Prior Credit Agreement provided for annual commitment fees ranging between 0.250% and 0.500% of the unused commitments under the prior revolving credit facility, depending on our total Net Leverage Ratio (as defined in the Prior Credit Agreement), and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin for the prior revolving credit facility, depending on our total Net Leverage Ratio (as defined in the Prior Credit Agreement). We incurred total such commitment fees of $0.4 million, $0.5 million, and $0.5 million during the years ended December 31, 2021, 2020, and 2019, respectively. Extensions of credit under the Credit Agreement are secured by guarantees from substantially all of the Company’s active material domestic subsidiaries and by security interests in substantially all of the Company’s and such subsidiaries’ assets, subject to certain specified exceptions. With respect to the Revolving Credit Facility, the Credit Agreement contains a financial covenant that requires us to comply with a specified maximum First Lien Net Leverage Ratio if utilization of the Revolving Credit Facility exceeds a specified level as of the last day of any period of four consecutive fiscal quarters. The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on the Company and certain of the Company’s subsidiaries with respect to, among other things, liens; indebtedness; changes in the nature of business; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); loans, advances, guarantees, acquisitions and other investments; restricted payments (including dividends, distributions, buybacks, redemptions and repurchases with respect to equity interests); change in fiscal year; prepayments, redemptions or acquisitions for value with respect to junior lien, subordinated or unsecured debt; changes in organizational documents and junior debt agreements; negative pledges; restrictions on subsidiary distributions; transfers of material assets to subsidiaries that are not guarantors; and transactions with affiliates. Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, the outstanding principal on the term loan under our Credit Agreement and the anticipated average monthly total participation levels of our members at our fitness partner locations, we currently believe we will be in compliance with the covenants under the Credit Agreement over the next 12 months. The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2022 — 2023 4,000 2024 4,000 2025 4,000 2026 4,000 2027 and thereafter 378,000 Total $ 394,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11 . Commitments and Contingencies Weiner Lawsuit On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of common stock, par value $0.001 per share (“Common Stock”) dropped on that same day. On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint (“Weiner Lawsuit”). The Weiner Lawsuit names as defendants the Company, the Company's former chief executive officer, chief financial officer, and a former executive who served as both chief accounting officer and interim chief financial officer. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release. . Shareholder Lawsuits: Strougo, Cobb, and Delaware Lawsuits On February 25, 2020, Robert Strougo, claiming to be a stockholder of the Company, filed a complaint in the United States District Court for the Middle District of Tennessee (the "Strougo Lawsuit"). On August 18, 2020, the Court appointed Sheet Metal Workers Local No. 33, Cleveland District, Pension Fund as lead plaintiff. Plaintiff filed its amended complaint on November 13, 2020. The amended complaint is on behalf of a putative class of stockholders who purchased Company Common Stock between March 8, 2019 and February 19, 2020 and names as defendants the Company, the Company's chief financial officer, former chief executive officer, and former president and chief operating officer. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the performance of and accounting for the Nutrisystem business that the Company acquired on March 8, 2019. The defendants filed a motion to dismiss the amended complaint on December 4, 2020. On July 29, 2021, the Court issued an order denying the defendants’ motion to dismiss. On October 26, 2021, Plaintiff filed a motion for class certification, which Defendants have opposed. The parties are currently engaged in discovery, and a trial date has been set for September 12, 2023. On April 9, 2020, John Cobb, claiming to be a stockholder of the Company, filed a derivative complaint in the United States District Court for the Middle District of Tennessee naming the Company as a nominal defendant and certain current and former directors and officers as defendants (the “Cobb Lawsuit”). The complaint asserts claims for breach of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste of corporate assets, largely tracking the factual allegations in the Strougo Lawsuit. The plaintiff seeks monetary damages on behalf of the Company, restitution, and certain corporate governance and internal procedural reforms. On June 9, 2020, the United States Magistrate Judge approved the parties’ stipulation to stay the case pending the resolution of defendants’ motion to dismiss in the Strougo Lawsuit. On August 23, 2021, the parties submitted another joint stipulation proposing to further extend the stay . In July 2020, three putative derivative complaints were filed in the United States District Court for the District of Delaware by the following individuals claiming to be stockholders of the Company: Patrick Yerby, Thomas R. Conte, Melvyn Klein, and Mark Ridendour (the “Delaware Derivative Lawsuits”). The complaints largely track the allegations, named defendants, asserted claims, and requested relief of the Cobb Lawsuit. The three Delaware Derivative Lawsuits have been consolidated. On August 24, 2021, the court entered an order staying the case. Given the uncertainty of litigation and the preliminary stage of the Strougo Lawsuit, Cobb Lawsuit, and Delaware Derivative Lawsuits, we are not currently able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against these lawsuits. Trademark Lawsuit: Pacific Packaging Lawsuit On May 31, 2019, Pacific Packaging Concepts, Inc. (“Pacific Packaging”) filed a complaint in the U.S. District Court for the Central District of California, Western Division, naming as defendants two former subsidiaries of the Company; Nutrisystem, Inc. and Nutri/System IPHC, Inc (“Pacific Packaging Lawsuit”). In its complaint, Pacific Packaging alleged that the defendants’ use of Pacific Packaging’s federally registered trademark, Fresh Start, in advertisements for its weight management program and shakes constitutes federal trademark infringement, counterfeit trademark infringement, false designation of origin, federal trademark dilution, unfair competition, false advertising, common law unfair competition, and common law trademark infringement. The complaint seeks injunctive relief and monetary damages in an unspecified amount. On August 29, 2019, the defendants filed their Answer to Complaint. On July 23, 2021, the Court granted the defendant’s motion for summary judgment dismissing certain of plaintiff’s damages claims, namely any claim for royalty damages and claims related to profits based on reverse confusion. The case was set for trial on March 1, 2022. In connection with the sale of Nutrisystem, the Company agreed to indemnify Kainos for losses arising out of this matter and retained the right to control the defense thereof. On January 11, 2022, the parties reached a settlement in principle of the Pacific Packaging Lawsuit pursuant to which defendants’ insurers will pay the entire settlement amount except for the amount of $25,000 representing the deductible on the policy, which will be paid by the Company pursuant to its indemnification agreement with Kainos. The settlement is subject to the negotiation and execution of a definitive written settlement agreement . Other Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise in the ordinary course of our business. Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies. As these matters are subject to inherent uncertainties, our view of these matters may change in the future. We expense legal costs as incurred

Investment in Equity Securities

Investment in Equity Securities	12 Months Ended
	Dec. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]
Investment in Equity Securities	12. Investment in Equity Securities At December 31, 2020 and during the first two quarters of 2021, w e owned 159,309 shares of common stock of a predecessor (“Legacy Sharecare”) of Sharecare, Inc. (“Sharecare”) that we acquired in connection with the sale of our total population health services business to Legacy Sharecare in July 2016. These shares did not have a readily determinable fair value through June 30, 2021. As permitted under ASC 321, “Investments – Equity Securities” (“ASC 321”), we elected to measure such shares at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer (of which there were none). The carrying value of the shares at December 31, 2020 of $10.8 million was reported in “Other assets” on our consolidated balance sheet in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (“2020 Form 10-K”) but has been reclassified in this report to a new line item, “Investment in equity securities, long-term.” On February 12, 2021, Legacy Sharecare announced that it had entered into a merger agreement with Falcon Capital Acquisition Corp. (“FCAC”) and FCAC Merger Sub, Inc. (“Merger Sub”) pursuant to which Legacy Sharecare would merge with and into Merger Sub with Sharecare surviving as a wholly owned subsidiary of FCAC (the “Sharecare Transaction”). The Sharecare Transaction was consummated effective July 1, 2021. As a result, our shares of common stock of Legacy Sharecare were converted into shares of common stock of Sharecare (“Sharecare Common Stock”), with 2.4% of such shares being converted into and paid to us in cash. Consequently, in July 2021, we received $2.7 million in cash as well as 11,079,331 shares of Sharecare Common Stock (“Sharecare Equity Security”). Our cost basis in the Sharecare Equity Security is $10.5 million or $0.95 average cost per share. Sharecare Common Stock began trading on The Nasdaq Stock Market LLC on July 2, 2021 under the trading symbol “SHCR”. The Sharecare Equity Security is subject to restrictions on resale, including a customary lockup period. The lockup period continues until the earlier of one year after the effective time of the Sharecare Transaction or such other time at which the Sharecare Common Stock trades at a certain minimum price for 20 trading days in any 30-day trading period beginning on or after November 28, 2021. In addition, between December 28, 2021 and March 27, 2022 (the “First Sale Window”), we are permitted to sell up to 750,000 shares. Between March 28, 2022 and July 1, 2022, we may sell up to 750,000 shares plus any portion of the 750,000 shares we were permitted to, but did not, sell during the First Sale Window. Subsequent to the consummation of the Sharecare Transaction in July 2021, the fair value of the Sharecare Equity Security became readily determinable. Accordingly, beginning in July 2021, we carry the Sharecare Equity Security on our consolidated balance sheet at fair value, and we recognize any changes in fair value of the Sharecare Equity Security in net income as unrealized gains or losses, as required under ASC 321. At December 31, 2021, the Sharecare Equity Security is reported as a current asset on our consolidated balance sheet in “Investment in equity securities”. During the year ended December 31, 2021, we recorded a realized gain of $2.5 million based on the $2.7 million cash proceeds received from the Sharecare Transaction, and we recorded an unrealized gain of $39.2 million based on the change in fair value of the Sharecare Equity Security. The realized and unrealized gain were each recorded to other (income) expense, net (see Note 17). During 2021, based on the positive evidence provided by the capital gains realized in the current year and anticipated to be realized from a future Equity Security we reversed $10.6 million of a valuation allowance of deferred tax assets related to capital loss carryforwards. Such reversal resulted in an income tax benefit that fully offset the income tax expense that would have otherwise resulted from the combined realized and unrealized gains of $41.7 million Equity Security Equity Security

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	1 3 . Fai Valu We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. Fair Value Hierarchy The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of each year, including the following: • reporting units measured at fair value as part of a goodwill impairment test; and • indefinite-lived intangible assets measured at fair value for impairment assessment. Each of these assets above is classified as Level 3 within the fair value hierarchy. The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date. Following the sale of Nutrisystem effective December 9, 2020, we have a single reporting unit. The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company. In March 2020, we experienced a significant decline in our market capitalization and in our actual and forecasted operating results, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets (which consisted of the Nutrisystem tradename and the SilverSneakers tradename). Following these evaluations, we recorded a total impairment loss of $199.5 million related to the Nutrisystem goodwill and tradename during the first quarter of 2020, which amount is reflected in loss from discontinued operations. We determined there was no impairment related to the SilverSneakers tradename or the carrying value of goodwill During the fourth quarter of 2021, we reviewed goodwill for impairment related to our single reporting unit. We estimated the fair value of the o Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents our financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020. December 31, 2021 December 31, 2020 Fair Value Measurements Using Input Types Fair Value Measurements Using Input Types (In thousands) Level 1 Level 2 Total Level 1 Level 2 Total Assets: Investment in equity securities (1) $ 49,746 $ — $ 49,746 $ — $ — $ — Total assets $ 49,746 $ — $ 49,746 $ — $ — $ — Liabilities: Derivatives designated as effective hedging instruments Interest rate swap agreements $ — $ 8,705 $ 8,705 $ — $ 20,377 $ 20,377 Non-designated derivatives Interest rate swap agreements $ — $ 6,938 $ 6,938 $ — $ 16,260 $ 16,260 Total liabilities $ — $ 15,643 $ 15,643 $ — $ 36,637 $ 36,637 (1) Reflects ownership of Sharecare Common Stock, as described in Note 12. At December 31, 2021, we held 11,079,331 shares of Sharecare Common Stock The fair value of the Sharecare Equity Security The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads. Fair Value of Other Financial Instruments The e a n n m a o Cash and cash equivalents – The carrying amount of $60.1 million approximates fair value because of the short maturity of those instruments (less than three months). Debt – The estimated fair value of outstanding borrowings under the Credit Agreement, which includes a term loan facility and a revolving credit facility (see Note 10), are determined based on the fair value hierarchy as discussed above. T he Term Loan B is actively traded and therefore is classified as a Level 1 valuation. The estimated fair value is based on an average of quotes as of December 31, 2021 from dealers who stand ready and willing to transact at those prices Th e volvin redi acilit he fair value of outstanding borrowings under the Term Loan B at December 31, 2021 was estimated to equal the carrying value inal issue discount and deferred loan costs) of $394.0 million. There were no outstanding borrowings under the Revolving Credit Facility at December 31 , 2021.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	1 4 . Deri v v n n a n v We use derivative instruments to manage differences in the amount, timing, and duration of our known or expected cash payments related to our outstanding debt (i.e., interest rate risk). Some of these derivatives are designated and qualify as a hedge of the exposure to variability in expected future cash flows and are therefore considered cash flow hedges. We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet at fair value as either an asset or liability. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. We classify cash flows from settlement of our effective cash flow hedges in the same category as the cash flows from the related hedged items, generally within the operating activities in the consolidated statements of cash flows. We classify cash flows from settlement of our non-designated derivatives within the investing section of the consolidated statements of cash flows. Cash Flow Hedges of Interest Rate Risk and Non-Designated Derivatives Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish these objectives, we primarily use interest rate swaps as part of our interest rate risk management strategy. The counterparties to the interest rate swap agreements expose us to credit risk in the event of nonperformance by such counterparties. However, at December 31, 2021, we do not anticipate nonperformance by these counterparties. Our interest rate swap agreements with each of the counterparties contain a provision whereby if we either default or are capable of being declared in default on any of our indebtedness, whether or not such default results in repayment of the indebtedness being accelerated by the lender, then we could also be declared in default on our derivative obligations. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for our making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in accumulated other comprehensive income or loss ("accumulated OCI") associated with such derivative instruments are reclassified into earnings in the period of de-designation. In May 2019, we entered into eight amortizing interest rate swap agreements, each of which matures in May 2024. Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2%. Upon entering into the Purchase Agreement with Kainos on October 18, 2020, we determined that some of our hedged transactions would not materially occur in the initially identified time period since we expected to use the majority of the net proceeds from the sale to pay down a significant portion of outstanding debt. As a result, we concluded that five of our eight interest rate swaps no longer qualified for hedge accounting treatment. Accordingly, in the fourth quarter of 2020 we de-designated these five derivatives (“de-designated swaps”) and accelerated the reclassification of deferred gains and losses in accumulated OCI to income (loss) from discontinued operations as a result of the hedged forecasted transactions becoming probable not to occur. Upon de-designation in the fourth quarter of 2020, we recognized a pre-tax loss of $14.3 million in income (loss) from discontinued operations. Additionally, upon de-designation in October 2020, we froze $3.2 million of previously deferred losses in accumulated OCI related to forecasted payments that are probable of occurring. We reclassify such deferred losses from accumulated OCI into earnings as an adjustment to interest expense during periods in which the forecasted transactions impact earnings , consistent with hedge accounting treatment. In the event that the related forecasted payments are probable of not occurring, the related loss in accumulated OCI will be recognized in earnings immediately. We continue to maintain the effective hedging relationship between three interest rate swap agreements and the portion of our forecasted payments that is expected to remain highly probable of occurring. Our entering into the Credit Agreement on June 30, 2021 had no effect on the hedging designation of our interest rate swaps as the hedges are not tied to a specific debt instrument and the economic characteristics of the Credit Agreement are similar to those of the Prior Credit Agreement. During the fourth quarter of 2020 we evaluated the likelihood and extent of potential future losses from the de-designated swaps. Such potential future losses are capped since the variable interest rate of our swaps is subject to a floor of 0%. Based on the LIBOR rates in effect at the time of de-designation, we decided to hold the de-designated swaps as derivative instruments requiring mark-to-market accounting treatment, with any change in fair value recognized each period in current earnings . At December 31, 2021, our interest rate swap agreements designated as effective cash flow hedges had current notional amounts totaling $333.3 million, and our de-designated interest rate swap agreements had current notional amounts totaling $266.7 million. We record all derivatives at estimated fair value in the consolidated balance sheet. Gains and losses on derivatives designated as effective cash flow hedges are recorded in accumulated OCI and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated OCI related to cash flow hedge derivatives will be reclassified to interest expense as we make interest payments on our variable-rate debt. As of December 31, 2021, we expect to reclassify $6.6 million, pre-tax, from accumulated OCI as an increase to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt. Gains and losses on derivatives de-designated as effective cash flow hedges are recorded in the consolidated statement of operations as other (income) expense, net. The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at December 31, 2021 and 2020 were as follows: (In thousands) December 31, 2021 December 31, 2020 Liabilities: Derivatives designated as effective hedging instruments: Current portion of long-term liabilities $ 5,911 $ 8,205 Other long-term liabilities 2,794 12,172 $ 8,705 $ 20,377 Non-designated derivatives: Current portion of long-term liabilities $ 4,714 $ 6,548 Other long-term liabilities 2,224 9,712 $ 6,938 $ 16,260 The following table presents the effect of cash flow hedge accounting on accumulated OCI as of December 31, 2021, 2020, and 2019: (In thousands) For the Year Ended December 31, 2021 December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments: (Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect (3,284 ) 33,247 16,930 Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect (8,388 ) (11,556 ) (692 ) Non-designated derivatives: Loss related to de-designation of ineffective portion of derivatives, gross of tax effect — (14,336 ) — Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect (600 ) (239 ) — Total other comprehensive (income) loss, gross of tax (12,272 ) 7,116 16,238 The following table presents the impact that non-designated derivatives had on our consolidated statement of operations for the years ended December 31, 2021 and 2020: (In thousands) Statement of Operations Classification Year Ended December 31, 2021 Year Ended December 31, 2020 Loss related to de-designation of ineffective portion of derivatives, gross of tax effect Income from discontinued operations, net of income tax $ — $ 14,336 Net (gain) loss related to ineffective portion of derivatives, gross of tax effect Other (income) expense, net (2,627 ) 226 (1) Previously deferred loss related to de-designated swaps reclassified from accumulated OCI, gross of tax effect Interest expense 600 239 $ (2,027 ) $ 14,801 (1) This amount was reported in “Selling, general and administrative expenses” on our consolidated statement of operations in our 2020 Form 10-K. We have reclassified it in this report to a new line item, “Other (income) expense, net”, to conform to current classifications.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	1 5 . Earning (L o ss Pe Sha r The i e o a u o n i o i d g o s e o ea r e e e 3 20 (In thousands except per share data) Year Ended December 31, Numerator: 2021 2020 2019 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 107,376 $ 56,869 $ 45,217 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share (2,462 ) (280,500 ) (332,038 ) Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 104,914 $ (223,631 ) $ (286,821 ) Denominator: Shares used for basic income (loss) per share 49,573 48,746 46,509 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 60 29 90 Restricted stock units 538 412 489 Performance-based stock units 69 29 15 Market stock units 184 1 — Shares used for diluted income (loss) per share 50,424 49,217 47,103 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 2.17 $ 1.17 $ 0.97 Discontinued operations $ (0.05 ) $ (5.75 ) $ (7.14 ) Net income (loss) (1) $ 2.12 $ (4.59 ) $ (6.17 ) Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 2.13 $ 1.16 $ 0.96 Discontinued operations $ (0.05 ) $ (5.70 ) $ (7.05 ) Net income (loss) $ 2.08 $ (4.54 ) $ (6.09 ) Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 226 186 70 Restricted stock units 20 242 192 Performance-based stock units — 24 — Restricted stock awards — 26 102 (1) Figures may not add due to rounding. Market stock units and performance-based stock units outstanding are considered contingently issuable shares, and certain of these stock units were excluded from the calculations of diluted earnings per share for all periods presented because the performance criteria had not been met as of the end of the applicable reporting period.

Accumulated OCI

Accumulated OCI	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Accumulated OCI	1 6 . Accumulated OCI The following tables summarize the changes in accumulated OCI, net of tax, for the years ended December 31, 2020 and 2021. (In thousands) Interest Rate Swaps Accumulated OCI, net of tax, as of January 1, 2020 $ (12,091 ) Other comprehensive income (loss) before reclassifications, net of tax of $8,491 (24,756 ) Amounts reclassified from accumulated OCI, net of tax of $6,674 19,458 Accumulated OCI, net of tax, as of December 31, 2020 $ (17,389 ) Other comprehensive income (loss) before reclassifications, net of tax of $838 2,446 Amounts reclassified from accumulated OCI, net of tax of $2,296 6,692 Accumulated OCI, net of tax, as of December 31, 2021 $ (8,251 ) The following table presents details about reclassifications out of accumulated OCI for the years ended December 31, 2021 and 2020: (In thousands) Year Ended December 31, 2021 Year Ended December 31, 2020 Statement of Operations Classification Interest rate swaps $ 8,988 $ 11,795 Interest expense (2,296 ) (3,012 ) Income tax — 10,675 Income from discontinued operations, net of income tax Total amounts reclassified from accumulated OCI $ 6,692 $ 19,458 Net of tax

Other (Income) Expense, Net

Other (Income) Expense, Net	12 Months Ended
	Dec. 31, 2021
Other Income And Expenses [Abstract]
Other (Income) Expense, Net	17. Other (Income) Expense, Net The following table shows the detail of Other (income) expense, net for the years ended December 31, 2021 and 2020. (In thousands) Year Ended December 31, 2021 Year Ended December 31, 2020 Unrealized gain on investment in equity securities (Note 12) $ (39,232 ) $ — Realized gain on investment in equity securities (Note 12) (2,469 ) — Unrealized (gain) loss related to ineffective portion of derivatives (Note 14) (2,627 ) 226 Other (income) expense, net $ (44,328 ) $ 226

Segment Disclosures and Concent

Segment Disclosures and Concentrations of Risk	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Disclosures and Concentrations of Risk	1 8 . Segment Disclosures and Concentrations of Risk Following the sale of Nutrisystem in December 2020, the results of which have been classified as discontinued operations for all periods presented, we have one operating and reportable segment. Therefore, all required segment information can be found in the consolidated financial statements. Our determination that we operate as a single segment is consistent with the financial information regularly viewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Geographic Information Long-lived assets and revenue from external customers attributable to our operations in the United States accounted for 100% . Major Customers and Concentration of Credit Risk During 2021 and 2020, our top three customers together accounted for 40% and 39%, respectively, of our revenues from continuing operations. Financial instruments that potentially subject us to concentrations of credit risk primarily include cash and cash equivalents, derivative financial instruments, and accounts receivable. Our cash and cash equivalents are placed with, and our derivative instruments are transacted with, major financial institutions. At December 31, 2021, we had two customers that each accounted for 10% or more of our accounts receivable, net and individually comprised approximately 22% and 35% of our consolidated accounts receivable, net at December 31, 2021. At December 31, 2020, we had two customers that each accounted for 10% or more of our accounts receivable, net and individually comprised approximately 26% and 33% of our consolidated accounts receivable, net at December 31, 2020.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	19 . Subsequent Event As discussed in Note 11, on January 11, 2022, we reached a settlement in principle of the Pacific Packaging Lawsuit pursuant to which our insurers will pay the entire settlement amount except for the amount of $25,000 (twenty-five thousand dollars) representing the deductible on the policy, which will be paid by the Company. Accordingly, as of December 31, 2021, we have recorded a current liability (in “Accrued liabilities”) equal to the entire settlement amount and a current asset (in “Other current assets”) equal to the settlement amount less $25,000.

Quarterly Financial Information

Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited)	2 0 . Quarterly Financial Info r mation (u na udite d ) The following tables contain selected unaudited statements of operations for each quarter of 2021 and 2020. As further discussed in Note 1, our results from continuing operations do not include the results of Nutrisystem, which we sold effective December 9, 2020. (In thousands, except per share data) Year Ended December 31, 2021 First Second Third Fourth (1) Revenues $ 108,085 $ 120,071 $ 126,289 $ 126,808 Gross margin 48,269 48,837 49,178 46,056 Income (loss) before income taxes 27,564 8,958 112,624 (15,424 ) Income (loss) from continuing operations 19,944 8,771 103,699 (25,038 ) Income (loss) from discontinued operations, net of income tax (808 ) (414 ) (932 ) (308 ) Net income (loss) 19,136 8,357 102,767 (25,346 ) Earnings (loss) per share – basic: Continuing operations (2) $ 0.41 $ 0.18 $ 2.09 $ (0.50 ) Discontinued operations (2) $ (0.02 ) $ (0.01 ) $ (0.02 ) $ (0.01 ) Net income (2)(3) $ 0.39 $ 0.17 $ 2.07 $ (0.51 ) Earnings (loss) per share – diluted: Continuing operations (2) $ 0.40 $ 0.17 $ 2.06 $ (0.50 ) Discontinued operations (2) $ (0.02 ) $ (0.01 ) $ (0.02 ) $ (0.01 ) Net income (2)(3) $ 0.38 $ 0.17 $ 2.04 $ (0.50 ) (In thousands, except per share data) Year Ended December 31, 2020 First Second Third Fourth (4) Revenues $ 159,692 $ 81,923 $ 95,481 $ 100,617 Gross margin 42,713 45,879 45,382 44,168 Income before income taxes 11,411 23,959 23,236 15,793 Income from continuing operations 8,275 17,202 16,750 14,642 Income (loss) from discontinued operations, net of income tax (206,381 ) 11,309 (59,168 ) (26,260 ) Net income (loss) (198,106 ) 28,511 (42,418 ) (11,618 ) Earnings (loss) per share – basic: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.30 Discontinued operations (2) $ (4.25 ) $ 0.23 $ (1.21 ) $ (0.54 ) Net income (loss) (2)(3) $ (4.08 ) $ 0.59 $ (0.87 ) $ (0.24 ) Earnings (loss) per share – diluted: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.29 Discontinued operations (2) $ (4.22 ) $ 0.23 $ (1.20 ) $ (0.53 ) Net income (loss) (2)(3) $ (4.05 ) $ 0.58 $ (0.86 ) $ (0.23 ) (1) Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3) Figures may not add due to rounding. (4) Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	a. Principles of Consolidation – See discussion above regarding Nutrisystem. We have eliminated all intercompany profits, transactions, and balances.
Cash and Cash Equivalents	b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit. Book cash overdrafts issued, but not yet presented to the bank for payment, are reclassified to accounts payable.
Accounts Receivable, net	Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed or products sold, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2021 and 2020. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables were $16.2 million and $5.7 million at December 31, 2021 and 2020, respectively, and
Investment in equity securities	d. Investment in equity securities – At December 31, 2021, investment in equity securities consists of 11,079,331 shares of common stock of Sharecare, Inc. As required under Accounting Standard Codification (“ASC”) 321, beginning in July 2021, we carry the investment at fair value and recognize any changes in fair value in net income as unrealized gains or losses. See Note 12 for further information on investment in equity securities.
Property and Equipment	e. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and office equipment, and three to five years for equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense, including depreciation of assets recorded under finance leases, for the years ended December 31, 2021, 2020, and 2019 was $11.3 million, $9.9 million, and $7.1 million, respectively.
Leases	f . Leases – We recognize right-of-use assets and lease liabilities for leases with contractual terms longer than twelve months, and we categorize such leases as either operating or finance. Finance leases are generally those leases that allow us to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. Our leases generally have remaining lease terms of seven to 33 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the asset or liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative fair values. Lease liabilities are recognized at the present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the leases. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Costs associated with right-of-use assets are recognized on a straight-line basis within operating expenses over the term of the lease. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. See Note 9 for further information on leases.
Intangible Assets	g . Intangible Assets - Intangible assets subject to amortization include acquired technology and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets related to continuing operations and subject to amortization were fully amortized at December 31, 2021 and 2020. Intangible assets related to continuing operations and not subject to amortization at December 31, 2021 and 2020 consist of a trade name of $29.0 million. In accordance with ASC 350, we review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. See Note 6 for further information on intangible assets.
Goodwill	h . Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. In accordance with ASC 350, we review g o odwill for i mp airm e nt at the rep o rting unit lev e l (op e rat i ng s e gment o r one level b e low an o perating s e gmen t ) on an a n nual bas i s ( d ur i ng the fourth q u arter of o u r fiscal year) or more frequ en t ly whenever events or circumsta n c e s i n dicate that th e carryin g v a lu e ma y no t b e r e cov e rab l e . Following the sale of our Nutrition business in December 2020, we have a single As part of the annual impairment test o e m n i o a n w i i o a n
Accounts Payable	i . Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
Accrued Liabilities	j . Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to fitness network locations (which actual visit data is typically received approximately one month in arrears)
Income Taxes	k . Income Taxes - We file a consolidated federal income tax return that includes all of our wholly owned subsidiaries. U.S. GAAP generally requires that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income.
Revenue Recognition	l . Revenue Recognition - See Note 4 for a further discussion of revenue recognition.
Marketing Expense	m . Marketing Expense – Marketing expense includes media, advertising production, marketing, and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense from continuing operations was $4.0 million, $7.2 million, and $7.1 million in 2021, 2020, and 2019, respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on a cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or, in the case of production costs, the first time the advertising takes place. At December 31, 2021 and 2020, $1.8 million and $0 million, respectively, of costs have been prepaid for future advertisements and promotions.
Earnings (Loss) Per Share	n . Earnings (Loss) Per Share – We calculate basic earnings (loss) per share using weighted average common shares outstanding during the period. We calculate diluted earnings (loss) per share using weighted average common shares outstanding during the period plus the effect of all dilutive potential common shares outstanding during the period unless the impact would be anti-dilutive. During 2019 and 2020, we used the two-class method to calculate earnings per share (“EPS”) as the unvested restricted stock awards outstanding under our equity incentive plan were participating shares with nonforfeitable rights to dividends. Under the two-class method, we computed earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period. In applying the two-class method, we allocated undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect was given to the participating securities because they did not share in the losses of the Company. There were no participating securities during 2021; as such, we did not calculate EPS using the two-class method during 2021. See
Share-Based Compensation	o . Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 7 for a further discussion of share-based compensation.
Derivative Instruments and Hedging Activities	p . Derivative Instruments and Hedging Activities – We generally use derivative instruments to add stability to interest expense and to manage our exposure to interest rate movements. We account for derivatives in accordance with Financial Accounting Standards Board (“FASB”) ASC Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. For derivatives that are designated and qualify as effective cash flow hedges, the unrealized gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings as interest expense when the hedged transaction affects earnings. If a derivative instrument ceases to be a highly effective hedge, we will discontinue hedge accounting prospectively for the affected derivative instrument. The application of the authoritative guidance could impact the volatility of earnings. See Note 14 for further information on derivative instruments and hedging activities.
Management Estimates	q . Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Relevant Accounting Standards	In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of December 31, 2021, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows . In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “ Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. In January 2021, the FASB issued ASU 2021-01, “Reference Rate Reform: Scope”, which refines the scope of ASC 848 and clarifies the application of its guidance. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship.

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations And Disposal Groups [Abstract]
Summary of Financial Results Included in Income (Loss) from Discontinued Operations	The following table presents financial results of the Nutrition business included in “loss from discontinued operations" for the years ended December 31, 2021, 2020 and 2019. Year Ended December 31 (In thousands) 2021 2020 (1) 2019 (2) Revenues $ — $ 617,191 $ 498,091 Cost of revenues — 291,097 232,240 Marketing expenses — 196,952 140,286 Selling, general and administrative expenses (3) 3,210 59,093 56,840 Depreciation and amortization — 35,957 43,638 Impairment loss — 199,500 377,100 Restructuring and related charges — 472 5,143 Interest expense (4) — 36,798 34,763 Pretax loss from discontinued operations (3,210 ) (202,678 ) (391,919 ) Loss on de-designation of cash flow hedges (5) — (14,336 ) — Write-off of deferred loan costs and debt discount (4) — (8,946 ) — Loss on sale of Nutrition business (6) (96 ) (101,391 ) — Total pretax loss from discontinued operations $ (3,306 ) $ (327,351 ) $ (391,919 ) Income tax benefit (844 ) (46,851 ) (59,881 ) Loss from discontinued operations, net of income tax benefit $ (2,462 ) $ (280,500 ) $ (332,038 ) (1) (2) (3) (4) The term loans under our Prior Credit Agreement (as defined in Note 10) were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Prior Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates. (5) (6) For the year ended December 31, 2020, the loss on sale of business consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 13), which includes post-closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem . During the year ended December 31, 2021, an additional loss of $ 0.1 million was recognized upon final settlement of the post- c losing working capital adjustment.
Summary of Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations	The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31 (In thousands) 2021 2020 2019 Impairment of goodwill and intangible assets $ — $ 199,500 $ 377,100 Loss on sale of business — 90,163 — Depreciation and amortization — 35,957 43,638 Loss on de-designation of cash flow hedges — 14,336 — Write-off of deferred loan costs and debt discount (1) — 8,946 — Capital expenditures on discontinued operations — 6,794 10,168 Share-based compensation on discontinued operations — 4,351 13,230 Deferred income taxes (844 ) (54,561 ) (68,488 ) (1) Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Summary of Revenue Disaggregated	The following table sets forth revenue from continuing operations disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Year Ended December 31 2021 2020 2019 SilverSneakers $ 362,767 $ 313,575 $ 492,778 Prime Fitness 94,254 95,015 120,949 WholeHealth Living 23,777 19,776 18,511 Other (1) 454 9,348 828 $ 481,252 $ 437,714 $ 633,066 (1) For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million of revenue from home-delivered meals.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment at December 31, 2021 and 2020 consisted of the following: (In thousands) December 31, 2021 December 31, 2020 Leasehold improvements $ 7,627 $ 7,963 Computer equipment and related software 57,095 45,504 Furniture and office equipment 2,683 4,418 Capital projects in process 2,071 1,262 Total property and equipment at cost $ 69,476 $ 59,147 Less: accumulated depreciation (44,229 ) (38,188 ) Total property and equipment, net $ 25,247 $ 20,959

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets Subject to Amortization	Intangible assets subject to amortization at December 31, 2021 and 2020 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Allocated Share-based Compensation Costs	Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2021, 2020, and 2019. We did not capitalize any share-based compensation costs during these periods. Year Ended December December December 31, (In millions) 2021 2020 2019 Share-based compensation included in cost of revenue $ 2.5 $ 2.7 $ 2.2 Share-based compensation included in selling, general and administrative expenses 7.6 6.2 3.4 Share-based compensation included in restructuring and related charges — 0.8 — Share-based compensation included in continuing operations $ 10.1 $ 9.7 $ 5.6 Share-based compensation included in discontinued operations — 4.4 13.2 Total share-based compensation $ 10.1 $ 14.1 $ 18.8 Total income tax benefit recognized in continuing operations 2.6 2.5 1.4
Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates	The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the years ended December 31, 2021 and 2020. There were no stock options granted during fiscal 2019. Year Ended December 2021 Year Ended December 2020 Year Ended December 2019 Weighted average grant-date fair value of options per share $ 13.31 $ 8.20 $ — Expected term (in years) 6.3 6.2 — Assumptions: Expected volatility 63.1 % 63.2 % — Expected dividends — — — Risk-free rate 1.4 % 0.7 % —
Summary of Stock Options	A summary of options as of December 31, 2021 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (In years) Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2021 422 $ 17.83 Granted 178 26.48 Exercised (81 ) 12.47 Forfeited (24 ) 17.64 Expired (2 ) 35.82 Outstanding at December 31, 2021 493 $ 21.75 5.4 $ 2,805 Exercisable at December 31, 2021 122 $ 22.82 3.4 $ 906
Summary of Restricted Stock Units	Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 1,241 $ 11.58 Granted 164 24.15 Vested (803 ) 11.43 Forfeited (21 ) 15.48 Nonvested at December 31, 2021 581 $ 15.20
Summary of Performance-Based Stock Units	Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 86 $ 20.30 Vested (84 ) 20.31 Forfeited (2 ) 19.71 Nonvested at December 31, 2021 — $ —
Summary of Market Stock Units	Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2021 150 $ 18.84 Nonvested at December 31, 2021 150 $ 18.84

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	Income tax expense is comprised of the following: Year Ended December 31, (In thousands) 2021 2020 2019 Current taxes: Federal $ 16,421 $ 526 $ 3,051 State 5,431 881 830 Deferred taxes: Federal 5,658 14,114 11,853 State (1,165 ) 2,009 4,559 Total $ 26,345 $ 17,530 $ 20,293
Significant Components of Net Deferred Tax Liability and Asset	The following table sets forth the significant components of our net deferred tax liability and asset as of December 31, 2021 and 2020: (In thousands) December 31, 2021 December 31, 2020 Deferred tax asset: Accruals and reserves $ 467 $ 1,137 Deferred compensation 169 604 Share-based payments 1,279 2,909 Lease liability 2,936 4,993 Section 163(j) interest limitation 2,902 370 Interest rate swap 2,830 5,964 Unrealized losses — 3,720 Net operating loss carryforwards 19,962 10,608 Capital loss carryforwards 145,330 149,608 175,875 179,913 Valuation allowance (148,754 ) (152,295 ) $ 27,121 $ 27,618 Deferred tax liability: Property and equipment $ (5,614 ) $ (4,516 ) Intangible assets (14,986 ) (14,868 ) Unrealized gains (6,972 ) — Right-of-use assets (2,732 ) (4,633 ) (30,304 ) (24,017 ) Net long-term deferred tax (liability) asset $ (3,183 ) $ 3,601
Difference between Income Tax Expense Computed using Statutory Federal Income Tax Rate and effective rate	The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2021 2020 2019 Statutory federal income tax $ 28,081 $ 15,624 $ 13,757 State income taxes, less federal income tax benefit 6,675 3,607 3,048 Executive compensation 2,172 1,062 150 Change in valuation allowance (14,275 ) (2,659 ) 2,509 Share-based compensation (2,644 ) 426 210 State income tax credits — — 954 Capital loss expiration 7,139 — — Prior year tax adjustments (970 ) (592 ) (464 ) Net impact of foreign operations 69 3 (9 ) Other 98 59 138 Income tax expense $ 26,345 $ 17,530 $ 20,293
Changes in Unrecognized Tax Benefits	The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows. There were no changes in unrecognized tax benefits during 2021. (In thousands) Unrecognized tax benefits at December 31, 2019 $ 1,061 Increases related to prior year tax positions 84 Decreases due to lapse of statute of limitations (20 ) Decreases related to Nutrisystem divestiture (1,125 ) Unrecognized tax benefits at December 31, 2020 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Right-of-Use Assets and Lease Liabilities	The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: December 31, 2021 December 31, 2020 (In thousands) Right-of-use assets: Operating $ 10,327 $ 17,145 Finance 368 994 Total leased assets $ 10,695 $ 18,139 Lease liabilities: Current Operating $ 7,610 $ 7,408 Finance 397 644 Non-current Operating $ 3,487 $ 11,097 Finance - 397 Total lease liabilities $ 11,494 $ 19,546
Schedule of Components of Lease Expense	The following table shows the components of lease expense: Year Ended December 31, Year Ended December 31, (In thousands) 2021 2020 Finance lease cost: Amortization of leased assets $ 626 $ 686 Interest of lease liabilities 42 86 Operating lease cost 7,578 7,872 Total lease cost before subleases $ 8,246 $ 8,644 Sublease income (5,377 ) (5,452 ) Total lease cost, net $ 2,869 $ 3,192
Schedule of Weighted Average Remaining Term and Discount Rates	The following provides information related to the lease term and discount rate as of December 31, 2021: Weighted Average Remaining Lease Term (years) Operating leases 1.7 Finance leases 0.6 Weighted Average Discount Rate Operating leases 4.9 % Finance leases 5.9 %
Schedule of Maturities of Lease Liabilities	As of December 31 aturities of lease liabilities for each of the next five years and thereafter were as follows: Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases 2022 7,957 (5,732 ) 2,225 403 2023 2,518 (957 ) 1,561 — 2024 1,083 — 1,083 — Total lease payments 11,558 $ (6,689 ) $ 4,869 403 Less: interest (461 ) (6 ) Present value of lease liabilities $ 11,097 $ 397
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Year Ended December 31, Year Ended December 31, (In thousands) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (3,921 ) $ (3,492 ) Operating cash flow attributable to finance leases (42 ) (86 ) Financing cash flow attributable to finance leases (642 ) (622 )

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount	The Company’s debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at December 31, 2021 and 2020 was as follows: (In thousands) December 31, 2021 December 31, 2020 Term Loan A $ — $ 124,035 Term Loan B 394,000 372,240 394,000 496,275 Less: deferred loan costs and original issue discount (13,496 ) (29,569 ) Total debt 380,504 466,706 Less: current portion — (7,456 ) Total long-term debt $ 380,504 $ 459,250
Summary of Effective Interest Rates Related to Continuing Operations for Term Loan A and Term Loan B	The following table shows the effective interest rates related to continuing operations for Term Loan A and Term Loan B (exclusive of payments related to de-designated interest rate swaps, which we do not classify as interest expense) for the years ended December 31, 2021 and 2020: For the Year Ended December 31, Effective interest rate per annum 2021 2020 Term Loan A under the Prior Credit Agreement 6.58 % 6.64 % Term Loan B under the Prior Credit Agreement 7.22 % 7.08 % Term Loan B under the Credit Agreement 6.52 % —
Minimum Annual Principal Payments and Repayments of the Revolving Advances	The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2022 — 2023 4,000 2024 4,000 2025 4,000 2026 4,000 2027 and thereafter 378,000 Total $ 394,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents our financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020. December 31, 2021 December 31, 2020 Fair Value Measurements Using Input Types Fair Value Measurements Using Input Types (In thousands) Level 1 Level 2 Total Level 1 Level 2 Total Assets: Investment in equity securities (1) $ 49,746 $ — $ 49,746 $ — $ — $ — Total assets $ 49,746 $ — $ 49,746 $ — $ — $ — Liabilities: Derivatives designated as effective hedging instruments Interest rate swap agreements $ — $ 8,705 $ 8,705 $ — $ 20,377 $ 20,377 Non-designated derivatives Interest rate swap agreements $ — $ 6,938 $ 6,938 $ — $ 16,260 $ 16,260 Total liabilities $ — $ 15,643 $ 15,643 $ — $ 36,637 $ 36,637 (1) Reflects ownership of Sharecare Common Stock, as described in Note 12. At December 31, 2021, we held 11,079,331 shares of Sharecare Common Stock

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet	The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at December 31, 2021 and 2020 were as follows: (In thousands) December 31, 2021 December 31, 2020 Liabilities: Derivatives designated as effective hedging instruments: Current portion of long-term liabilities $ 5,911 $ 8,205 Other long-term liabilities 2,794 12,172 $ 8,705 $ 20,377 Non-designated derivatives: Current portion of long-term liabilities $ 4,714 $ 6,548 Other long-term liabilities 2,224 9,712 $ 6,938 $ 16,260
Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI	The following table presents the effect of cash flow hedge accounting on accumulated OCI as of December 31, 2021, 2020, and 2019: (In thousands) For the Year Ended December 31, 2021 December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments: (Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect (3,284 ) 33,247 16,930 Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect (8,388 ) (11,556 ) (692 ) Non-designated derivatives: Loss related to de-designation of ineffective portion of derivatives, gross of tax effect — (14,336 ) — Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect (600 ) (239 ) — Total other comprehensive (income) loss, gross of tax (12,272 ) 7,116 16,238
Schedule of Impact of Derivatives Not Designated as Hedges on Consolidated Statement of Operations	The following table presents the impact that non-designated derivatives had on our consolidated statement of operations for the years ended December 31, 2021 and 2020: (In thousands) Statement of Operations Classification Year Ended December 31, 2021 Year Ended December 31, 2020 Loss related to de-designation of ineffective portion of derivatives, gross of tax effect Income from discontinued operations, net of income tax $ — $ 14,336 Net (gain) loss related to ineffective portion of derivatives, gross of tax effect Other (income) expense, net (2,627 ) 226 (1) Previously deferred loss related to de-designated swaps reclassified from accumulated OCI, gross of tax effect Interest expense 600 239 $ (2,027 ) $ 14,801 (1) This amount was reported in “Selling, general and administrative expenses” on our consolidated statement of operations in our 2020 Form 10-K. We have reclassified it in this report to a new line item, “Other (income) expense, net”, to conform to current classifications.

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share	The i e o a u o n i o i d g o s e o ea r e e e 3 20 (In thousands except per share data) Year Ended December 31, Numerator: 2021 2020 2019 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 107,376 $ 56,869 $ 45,217 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share (2,462 ) (280,500 ) (332,038 ) Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 104,914 $ (223,631 ) $ (286,821 ) Denominator: Shares used for basic income (loss) per share 49,573 48,746 46,509 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 60 29 90 Restricted stock units 538 412 489 Performance-based stock units 69 29 15 Market stock units 184 1 — Shares used for diluted income (loss) per share 50,424 49,217 47,103 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 2.17 $ 1.17 $ 0.97 Discontinued operations $ (0.05 ) $ (5.75 ) $ (7.14 ) Net income (loss) (1) $ 2.12 $ (4.59 ) $ (6.17 ) Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 2.13 $ 1.16 $ 0.96 Discontinued operations $ (0.05 ) $ (5.70 ) $ (7.05 ) Net income (loss) $ 2.08 $ (4.54 ) $ (6.09 ) Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 226 186 70 Restricted stock units 20 242 192 Performance-based stock units — 24 — Restricted stock awards — 26 102 (1) Figures may not add due to rounding.

Accumulated OCI (Tables)

Accumulated OCI (Tables)	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Changes in Accumulated OCI	The following tables summarize the changes in accumulated OCI, net of tax, for the years ended December 31, 2020 and 2021. (In thousands) Interest Rate Swaps Accumulated OCI, net of tax, as of January 1, 2020 $ (12,091 ) Other comprehensive income (loss) before reclassifications, net of tax of $8,491 (24,756 ) Amounts reclassified from accumulated OCI, net of tax of $6,674 19,458 Accumulated OCI, net of tax, as of December 31, 2020 $ (17,389 ) Other comprehensive income (loss) before reclassifications, net of tax of $838 2,446 Amounts reclassified from accumulated OCI, net of tax of $2,296 6,692 Accumulated OCI, net of tax, as of December 31, 2021 $ (8,251 )
Schedule of Reclassifications Out of Accumulated OCI	The following table presents details about reclassifications out of accumulated OCI for the years ended December 31, 2021 and 2020: (In thousands) Year Ended December 31, 2021 Year Ended December 31, 2020 Statement of Operations Classification Interest rate swaps $ 8,988 $ 11,795 Interest expense (2,296 ) (3,012 ) Income tax — 10,675 Income from discontinued operations, net of income tax Total amounts reclassified from accumulated OCI $ 6,692 $ 19,458 Net of tax

Other (Income) Expense, Net (Ta

Other (Income) Expense, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income And Expenses [Abstract]
Summary of Other (Income) Expense, Net	The following table shows the detail of Other (income) expense, net for the years ended December 31, 2021 and 2020. (In thousands) Year Ended December 31, 2021 Year Ended December 31, 2020 Unrealized gain on investment in equity securities (Note 12) $ (39,232 ) $ — Realized gain on investment in equity securities (Note 12) (2,469 ) — Unrealized (gain) loss related to ineffective portion of derivatives (Note 14) (2,627 ) 226 Other (income) expense, net $ (44,328 ) $ 226

Quarterly Financial Informati_2

Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following tables contain selected unaudited statements of operations for each quarter of 2021 and 2020. As further discussed in Note 1, our results from continuing operations do not include the results of Nutrisystem, which we sold effective December 9, 2020. (In thousands, except per share data) Year Ended December 31, 2021 First Second Third Fourth (1) Revenues $ 108,085 $ 120,071 $ 126,289 $ 126,808 Gross margin 48,269 48,837 49,178 46,056 Income (loss) before income taxes 27,564 8,958 112,624 (15,424 ) Income (loss) from continuing operations 19,944 8,771 103,699 (25,038 ) Income (loss) from discontinued operations, net of income tax (808 ) (414 ) (932 ) (308 ) Net income (loss) 19,136 8,357 102,767 (25,346 ) Earnings (loss) per share – basic: Continuing operations (2) $ 0.41 $ 0.18 $ 2.09 $ (0.50 ) Discontinued operations (2) $ (0.02 ) $ (0.01 ) $ (0.02 ) $ (0.01 ) Net income (2)(3) $ 0.39 $ 0.17 $ 2.07 $ (0.51 ) Earnings (loss) per share – diluted: Continuing operations (2) $ 0.40 $ 0.17 $ 2.06 $ (0.50 ) Discontinued operations (2) $ (0.02 ) $ (0.01 ) $ (0.02 ) $ (0.01 ) Net income (2)(3) $ 0.38 $ 0.17 $ 2.04 $ (0.50 ) (In thousands, except per share data) Year Ended December 31, 2020 First Second Third Fourth (4) Revenues $ 159,692 $ 81,923 $ 95,481 $ 100,617 Gross margin 42,713 45,879 45,382 44,168 Income before income taxes 11,411 23,959 23,236 15,793 Income from continuing operations 8,275 17,202 16,750 14,642 Income (loss) from discontinued operations, net of income tax (206,381 ) 11,309 (59,168 ) (26,260 ) Net income (loss) (198,106 ) 28,511 (42,418 ) (11,618 ) Earnings (loss) per share – basic: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.30 Discontinued operations (2) $ (4.25 ) $ 0.23 $ (1.21 ) $ (0.54 ) Net income (loss) (2)(3) $ (4.08 ) $ 0.59 $ (0.87 ) $ (0.24 ) Earnings (loss) per share – diluted: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.29 Discontinued operations (2) $ (4.22 ) $ 0.23 $ (1.20 ) $ (0.53 ) Net income (loss) (2)(3) $ (4.05 ) $ 0.58 $ (0.86 ) $ (0.23 ) (1) Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3) Figures may not add due to rounding. (4) Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)Segmentshares	Dec. 31, 2020USD ($)Segmentshares	Dec. 31, 2019USD ($)	Jul. 31, 2021shares
Accounting Policies [Line Items]
Allowance for doubtful accounts	$ 0	$ 0
Unbilled receivables	$ 16,200	$ 5,700
Common stock, shares outstanding (in shares) | shares	49,800,756	48,983,735
Depreciation expense	$ 11,298	$ 9,930	$ 7,137
Number of reporting units | Segment	1	1
Accrued liabilities	$ 28,270	$ 18,424
Continuing Operations
Accounting Policies [Line Items]
Number of reporting units | Segment	1
Media expense	$ 4,000	7,200	$ 7,100
Prepaid for future advertisements and promotions	1,800	0
Network Locations Visits
Accounting Policies [Line Items]
Accrued liabilities	19,300	10,500
Tradename
Accounting Policies [Line Items]
Intangible assets not subject to amortization	$ 29,000	$ 29,000
Minimum
Accounting Policies [Line Items]
Remaining lease terms	7 months
Estimated useful life	3 years	3 years
Maximum
Accounting Policies [Line Items]
Remaining lease terms	33 months
Estimated useful life	10 years	10 years
Computer Software and Hardware | Minimum
Accounting Policies [Line Items]
Useful life	3 years
Computer Software and Hardware | Maximum
Accounting Policies [Line Items]
Useful life	7 years
Furniture and Office Equipment | Minimum
Accounting Policies [Line Items]
Useful life	4 years
Furniture and Office Equipment | Maximum
Accounting Policies [Line Items]
Useful life	7 years
Equipment | Minimum
Accounting Policies [Line Items]
Useful life	3 years
Equipment | Maximum
Accounting Policies [Line Items]
Useful life	5 years
Leasehold Improvements | Minimum
Accounting Policies [Line Items]
Useful life	2 years
Leasehold Improvements | Maximum
Accounting Policies [Line Items]
Useful life	15 years
Sharecare
Accounting Policies [Line Items]
Common stock, shares outstanding (in shares) | shares	11,079,331			11,079,331

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Dec. 09, 2020
Business Acquisition [Line Items]
Proceeds from sale of Nutrition business, net of cash transferred	$ 2,747	$ 558,067
Nutrisystem, Inc.
Business Acquisition [Line Items]
Customary indebtedness and cash adjustments				$ 558,900
Transaction costs directly related to disposition of Nutrition		11,200
Proceeds from sale of Nutrition business, net of cash transferred		$ 550,400
Nutrisystem, Inc. | Other Current Assets
Business Acquisition [Line Items]
Additional proceeds from sale of businesses after working capital adjustment			$ 2,700

Discontinued Operations - Summa

Discontinued Operations - Summary of Financial Results Included in Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Impairment loss				$ 199,500		$ 377,100
Write-off of deferred loan costs and debt discount	[1]			(8,946)
Income tax benefit			$ 844	46,851		59,881
Loss from discontinued operations, net of income tax benefit			(2,462)	(280,500)		(332,038)
Nutrisystem, Inc.
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Revenues				617,191	[2]	498,091	[3]
Cost of revenues				291,097	[2]	232,240	[3]
Marketing expenses				196,952	[2]	140,286	[3]
Selling, general and administrative expenses	[4]		3,210	59,093	[2]	56,840	[3]
Depreciation and amortization				35,957	[2]	43,638	[3]
Impairment loss		$ 199,500		199,500	[2]	377,100	[3]
Restructuring and related charges				472	[2]	5,143	[3]
Interest expense	[5]			36,798	[2]	34,763	[3]
Pretax loss from discontinued operations			(3,210)	(202,678)	[2]	(391,919)	[3]
Loss on de-designation of cash flow hedges	[2],[6]			(14,336)
Write-off of deferred loan costs and debt discount	[2],[5]			(8,946)
Loss on sale of Nutrition business	[7]		(96)	(101,391)	[2]
Total pretax loss from discontinued operations			(3,306)	(327,351)	[2]	(391,919)	[3]
Income tax benefit			(844)	(46,851)	[2]	(59,881)	[3]
Loss from discontinued operations, net of income tax benefit			$ (2,462)	$ (280,500)	[2]	$ (332,038)	[3]
[1]	Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.
[2]
[3]
[4]
[5]	The term loans under our Prior Credit Agreement (as defined in Note 10) were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Prior Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates.
[6]
[7]	For the year ended December 31, 2020, the loss on sale of business consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 13), which includes post-closing adjustments related to final

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Financial Results Included in Income (Loss) from Discontinued Operations (Parenthetical) (Details) - USD ($) $ in Thousands		Dec. 09, 2020	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019	[3]	Dec. 08, 2020
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional loss recognized				$ (90,163)
Nutrisystem, Inc.
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Interest expense	[2]			36,798	[1]	$ 34,763
Impairment losses				90,200
Transaction costs directly related to disposition of Nutrition				$ 11,200
Additional loss recognized			$ 100
Nutrisystem, Inc. | Long-term Debt
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Interest expense								$ 519,000
Nutrisystem, Inc. | Long-term Debt | Prior Credit Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Repayment of principal on the term loan		$ 519,000
[1]
[2]	The term loans under our Prior Credit Agreement (as defined in Note 10) were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Prior Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates.
[3]

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operation Alternative Cash Flow Information [Abstract]
Impairment of goodwill and intangible assets			$ 199,500	$ 377,100
Loss on sale of business			90,163
Depreciation and amortization			35,957	43,638
Loss on de-designation of cash flow hedges			14,336
Write-off of deferred loan costs and debt discount	[1]		8,946
Capital expenditures on discontinued operations			6,794	10,168
Share-based compensation on discontinued operations			4,351	13,230
Deferred income taxes		$ (844)	$ (54,561)	$ (68,488)
[1]	Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)SegmentProgramObligation	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Disaggregation Of Revenue [Line Items]
Deferred revenue	$ 3,371	$ 4,460
Increase to deferred revenue	$ (1,089)	$ 686	$ (1,198)
Number of reportable segments | Segment	1	1
Continuing Operations
Disaggregation Of Revenue [Line Items]
Number of programs | Program	3
Number of performance obligations | Obligation	1
Deferred revenue	$ 3,400	$ 4,500
Revenue recognized	4,400
Increase to deferred revenue	3,300
Revenue recognized from performance obligations satisfied in prior period	$ 100
Period of billing in arrears once timing of services to customers is known	1 month
Number of days for customer to make payment after being invoiced	30 days
Capitalized costs	$ 300	800
Capitalized costs, amortization expense	$ 700	$ 400	$ 100
Number of reportable segments | Segment	1
Continuing Operations | SilverSneakers
Disaggregation Of Revenue [Line Items]
Revenues from PMPM fees percentage	47.00%	54.00%

Revenue Recognition - Summary o

Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2021

[1]

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Dec. 31, 2020

[2]

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Disaggregation Of Revenue [Line Items]

Revenue

$ 126,808

$ 126,289

$ 120,071

$ 108,085

$ 100,617

$ 95,481

$ 81,923

$ 159,692

$ 481,252

$ 437,714

$ 633,066

Continuing Operations

Disaggregation Of Revenue [Line Items]

Revenue

481,252

437,714

633,066

Continuing Operations | SilverSneakers

Disaggregation Of Revenue [Line Items]

Revenue

362,767

313,575

492,778

Continuing Operations | Prime Fitness

Disaggregation Of Revenue [Line Items]

Revenue

94,254

95,015

120,949

Continuing Operations | WholeHealth Living

Disaggregation Of Revenue [Line Items]

Revenue

23,777

19,776

18,511

Continuing Operations | Other

Disaggregation Of Revenue [Line Items]

Revenue

[3]

$ 454

$ 9,348

$ 828

[1]

Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses

[2]

Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

[3]

For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million of revenue from home-delivered meals.

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2021

[1]

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Dec. 31, 2020

[2]

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Disaggregation Of Revenue [Line Items]

Revenue

$ 126,808

$ 126,289

$ 120,071

$ 108,085

$ 100,617

$ 95,481

$ 81,923

$ 159,692

$ 481,252

$ 437,714

$ 633,066

Well-Being Program

Disaggregation Of Revenue [Line Items]

Revenue

6,800

Wisely Well brand

Disaggregation Of Revenue [Line Items]

Revenue

$ 2,200

[1]

Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses

[2]

Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 69,476	$ 59,147
Less: accumulated depreciation	(44,229)	(38,188)
Total property and equipment, net	25,247	20,959
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment at cost	7,627	7,963
Computer Equipment and Related Software
Property Plant And Equipment [Line Items]
Total property and equipment at cost	57,095	45,504
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Total property and equipment at cost	2,683	4,418
Capital Projects in Process
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 2,071	$ 1,262

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross amount of goodwill of continuing operations	$ 517,000,000	$ 517,000,000
Accumulated impairment losses	182,400,000	182,400,000
Amortization	0	0	$ 0
Expected amortization expense, 2022	0
Expected amortization expense, 2023	0
Expected amortization expense, 2024	0
Expected amortization expense, 2025	0
Expected amortization expense, 2026	0
Expected amortization expense, thereafter	0
Tradename
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization	$ 29,000,000	$ 29,000,000

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,192	$ 10,192
Accumulated Amortization	(10,192)	(10,192)
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,483	1,483
Accumulated Amortization	(1,483)	(1,483)
Distributor and Provider Networks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,709	8,709
Accumulated Amortization	$ (8,709)	$ (8,709)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)Type$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Types of share based awards | Type	4
Share based awards, description	During 2021 we had four types of share-based awards outstanding to our employees and directors: stock options, restricted stock units, performance-based stock units, and market stock units. All performance-based stock units were vested as of December 31, 2021.
Number of shares reserved for future equity grants (in shares) | shares	1,100,000
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted | $	$ 10,200
Weighted average period for recognition of unrecognized compensation cost	1 year 4 months 24 days
Stock options granted during period | shares	178,000		0
Total intrinsic value of options exercised during period | $	$ 900	$ 600	$ 600
Cash received from option exercised | $	686	1,025	989
Tax benefit realized from options exercised | $	200
Total grant-date fair value of shares vested | $	$ 10,900	$ 13,600	$ 23,500
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	3 years
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, expiration period	7 years
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, fair value | $ / shares	$ 24.15	$ 11.17	$ 19.68
Share based awards, granted | shares	164,000
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	3 years
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	4 years
Performance-Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, fair value | $ / shares	$ 21.49	$ 20.20
Share based awards, granted | shares	0
Performance-Based Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	2 years
Performance-Based Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	3 years
Market Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period	3 years
Share based awards, fair value | $ / shares	$ 18.84
Share based awards, granted | shares		0	0

Share-Based Compensation - Allo

Share-Based Compensation - Allocated Share-based Compensation Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	$ 10.1	$ 14.1	$ 18.8
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	2.5	2.7	2.2
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	7.6	6.2	3.4
Restructuring and Related Charges
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs		0.8
Continuing Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	10.1	9.7	5.6
Total income tax benefit recognized in continuing operations	$ 2.6	2.5	1.4
Discontinued Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs		$ 4.4	$ 13.2

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options per share	$ 13.31	$ 8.20
Expected term (in years)	6 years 3 months 18 days	6 years 2 months 12 days
Assumptions:
Expected volatility	63.10%	63.20%
Risk-free rate	1.40%	0.70%

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
Shares [Roll Forward]
Outstanding, beginning of period (in shares)	422,000
Granted (in shares)	178,000	0
Exercised (in shares)	(81,000)
Forfeited (in shares)	(24,000)
Expired (in shares)	(2,000)
Outstanding, end of period (in shares)	493,000
Exercisable, end of period (in shares)	122,000
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 17.83
Granted (in dollars per share)	26.48
Exercised (in dollars per share)	12.47
Forfeited (in dollars per share)	17.64
Expired (in dollars per share)	35.82
Outstanding, end of period (in dollars per share)	21.75
Exercisable, end of period (in dollars per share)	$ 22.82
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	5 years 4 months 24 days
Exercisable	3 years 4 months 24 days
Aggregate Intrinsic Value [Abstract]
Outstanding, end of period	$ 2,805
Exercisable, end of period	$ 906

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shares [Roll Forward]
Nonvested, beginning of period (in shares)	1,241
Granted (in shares)	164
Vested (in shares)	(803)
Forfeited (in shares)	(21)
Nonvested, end of period (in shares)	581	1,241
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)	$ 11.58
Granted (in dollars per share)	24.15	$ 11.17	$ 19.68
Vested (in dollars per share)	11.43
Forfeited (in dollars per share)	15.48
Nonvested, end of period (in dollars per share)	$ 15.20	$ 11.58

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Performance-Based Stock Units (Details) - Performance-Based Stock Units shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Shares [Roll Forward]
Nonvested, beginning of period (in shares) | shares	86
Vested (in shares) | shares	(84)
Forfeited (in shares) | shares	(2)
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share) | $ / shares	$ 20.30
Vested (in dollars per share) | $ / shares	20.31
Forfeited (in dollars per share) | $ / shares	$ 19.71

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Market Stock Units (Details) - Market Stock Units shares in Thousands	Dec. 31, 2021$ / sharesshares
Shares [Roll Forward]
Nonvested, beginning of period (in shares) | shares	150
Nonvested, end of period (in shares) | shares	150
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share) | $ / shares	$ 18.84
Nonvested, end of period (in dollars per share) | $ / shares	$ 18.84

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current taxes [Abstract]
Federal	$ 16,421	$ 526	$ 3,051
State	5,431	881	830
Deferred taxes [Abstract]
Federal	5,658	14,114	11,853
State	(1,165)	2,009	4,559
Total	$ 26,345	$ 17,530	$ 20,293

Income Taxes - Significant Comp

Income Taxes - Significant Components of Net Deferred Tax Liability and Asset (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax asset [Abstract]
Accruals and reserves	$ 467	$ 1,137
Deferred compensation	169	604
Share-based payments	1,279	2,909
Lease liability	2,936	4,993
Section 163(j) interest limitation	2,902	370
Interest rate swap	2,830	5,964
Unrealized losses	0	3,720
Net operating loss carryforwards	19,962	10,608
Capital loss carryforwards	145,330	149,608
Deferred tax assets, gross	175,875	179,913
Valuation allowance	(148,754)	(152,295)
Total	27,121	27,618
Deferred tax liability [Abstract]
Property and equipment	(5,614)	(4,516)
Intangible assets	(14,986)	(14,868)
Unrealized gains	(6,972)	0
Right-of-use assets	(2,732)	(4,633)
Total	(30,304)	(24,017)
Net long-term deferred tax liability	$ (3,183)
Net long-term deferred tax asset		$ 3,601

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 17, 2022
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards	$ (3,500,000)
Increase in income tax expense			$ 2,700,000
Capital loss carryforwards	145,330,000	$ 149,608,000
Unrealized gain	39,200,000
Valuation allowance	148,754,000	152,295,000
Tax effect related to interest rate swap agreements	2,830,000	5,964,000
Unrecognized tax benefits	0	1,100,000	1,061,000
Unrecognized tax benefits that affect our effective tax rate	$ 0
Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year	2018
Sharecare
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards	$ (9,900,000)
Tax credit carryforwards	$ 573,400,000
Tax credit carryforwards, expiration dates	Dec. 31, 2025
Indefinite Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 8,000,000
Nutrisystem, Inc.
Operating Loss Carryforwards [Line Items]
Capital loss carryforwards				$ 135,400,000
International
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards valuation allowance	2,400,000
Operating loss carryforwards	8,300,000
State
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards		$ (2,700,000)	1,800,000
Reduction in deferred tax asset related to income tax credits			$ 900,000
Operating loss carry forwards valuation allowance	11,000,000
Operating loss carryforwards	$ 344,100,000
State | Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2026
State | Latest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2040

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Difference Between Income Tax Expense Computed Using Statutory Federal Income Tax Rate And Effective Rate [Abstract]
Statutory federal income tax	$ 28,081	$ 15,624	$ 13,757
State income taxes, less federal income tax benefit	6,675	3,607	3,048
Executive compensation	2,172	1,062	150
Change in valuation allowance	(14,275)	(2,659)	2,509
Share-based compensation	(2,644)	426	210
State income tax credits			954
Capital loss expiration	7,139
Prior year tax adjustments	(970)	(592)	(464)
Net impact of foreign operations	69	3	(9)
Other	98	59	138
Total	$ 26,345	$ 17,530	$ 20,293

Income Taxes - Uncertain Tax Po

Income Taxes - Uncertain Tax Positions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Changes in Unrecognized Tax Benefits [Roll Forward]
Balance, beginning of period	$ 1,061
Increases related to prior year tax positions	84
Decreases due to lapse of statute of limitations	(20)
Decreases related to Nutrisystem divestiture	(1,125)
Balance, end of period	$ 1,100

Leases - Additional Information

Leases - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021Agreement
Lessee Lease Description [Line Items]
Number of sublease agreements	2
Minimum
Lessee Lease Description [Line Items]
Remaining lease terms	7 months
Maximum
Lessee Lease Description [Line Items]
Remaining lease terms	33 months

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Right-of-use assets:
Operating	$ 10,327	$ 17,145
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
Finance	$ 368	$ 994
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets	us-gaap:OtherAssets
Total leased assets	$ 10,695	$ 18,139
Current
Operating	$ 7,610	$ 7,408
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherLiabilitiesCurrent	us-gaap:OtherLiabilitiesCurrent
Finance	$ 397	$ 644
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherLiabilitiesCurrent	us-gaap:OtherLiabilitiesCurrent
Non-current
Operating	$ 3,487	$ 11,097
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Finance		$ 397
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Total lease liabilities	$ 11,494	$ 19,546

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Amortization of leased assets	$ 626	$ 686
Interest of lease liabilities	42	86
Operating lease cost	7,578	7,872
Total lease cost before subleases	8,246	8,644
Sublease income	(5,377)	(5,452)
Total lease cost, net	$ 2,869	$ 3,192

Leases - Schedule of Weighted A

Leases - Schedule of Weighted Average Remaining Term and Discount Rates (Details)	Dec. 31, 2021
Weighted Average Remaining Lease Term (years)
Operating leases, Weighted average remaining lease term (years)	1 year 8 months 12 days
Finance leases, Weighted average remaining lease term (years)	7 months 6 days
Weighted Average Discount Rate
Operating leases, Weighted average discount rate	4.90%
Finance leases, Weighted average discount rate	5.90%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Operating Leases Lease Payments
2022	$ 7,957
2023	2,518
2024	1,083
Total lease payments	11,558
Less: interest	(461)
Present value of lease liabilities	11,097
Operating Leases Sublease Receipts
2022	(5,732)
2023	(957)
Total Operating Leases Sublease Receipts	(6,689)
Operating Leases Net
2022	2,225
2023	1,561
2024	1,083
Total operating lease payments Net	4,869
Financing Leases
2022	403
Total lease payments	403
Less: interest	(6)
Present value of lease liabilities	$ 397

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases	$ (3,921)	$ (3,492)
Operating cash flow attributable to finance leases	(42)	(86)
Financing cash flow attributable to finance leases	$ (642)	$ (622)

Debt - Credit Facility - Additi

Debt - Credit Facility - Additional Information (Details)	Jun. 30, 2021USD ($)	Mar. 08, 2019	Oct. 31, 2021USD ($)	May 31, 2019Agreement	Dec. 31, 2021USD ($)Agreement	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Line Of Credit Facility [Line Items]
Outstanding debt					$ 380,504,000	$ 466,706,000
Non-cash loss on extinguishment of debt					18,237,000
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Available borrowing capacity					99,500,000
Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date	Jun. 30, 2021
Outstanding debt					380,500,000
Non-cash loss on extinguishment of debt	$ 18,200,000
Loss on modification of debt	800,000
Excess cash flow amount	$ 10,000
Commitment fees					$ 400,000	$ 500,000	$ 500,000
Credit Agreement | Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.25%
Credit Agreement | Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.375%
Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Periodic principal payment as percentage of aggregate principal amount	0.25%
Payments on term loans			$ 5,000,000
Maturity date	Jun. 30, 2028		Dec. 31, 2022
Effective interest rates					6.52%
Debt instrument, face amount	$ 400,000,000
Percentage of premium with respect to the principal of term loan B	1.00%
Debt instrument, term	6 months
Credit Agreement | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maturity date					Jun. 30, 2026
Maximum borrowing capacity	$ 100,000,000
Credit Agreement | Swingline Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 30,000,000
Credit Agreement | Prior Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date	Mar. 8, 2019
Credit Agreement | Letters of Credit Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 40,000,000
Credit Agreement | Uncommitted Incremental Accordion Facility
Line Of Credit Facility [Line Items]
Percentage of consolidated EBITDA requirement	100.00%
Credit Agreement | Uncommitted Incremental Accordion Facility | Minimum
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 167,500,000
Credit Agreement | First Lien Net Leverage Ratio is Greater than 3.25:1
Line Of Credit Facility [Line Items]
Excess cash flow percentages	50.00%
Credit Agreement | First Lien Net Leverage Ratio Is Less than Or Equal to 3.25:1 But Greater than 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentages	25.00%
Credit Agreement | First Lien Net Leverage Ratio is Less than or Equal to 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentages	0.00%
Credit Agreement | LIBOR | Minimum
Line Of Credit Facility [Line Items]
Variable rate basis	0.00%
Credit Agreement | LIBOR | Term Loan Facility B
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | LIBOR | Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Margin rate	3.75%
Credit Agreement | LIBOR | Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Credit Agreement | One-Month LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement | Base Rate | Minimum
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement | Base Rate | Term Loan Facility B
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement | Base Rate | Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Margin rate	2.75%
Credit Agreement | Base Rate | Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Prior Credit Agreement | Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage		0.25%
Prior Credit Agreement | Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage		0.50%
Prior Credit Agreement | Term Loan Facility A
Line Of Credit Facility [Line Items]
Effective interest rates					6.58%	6.64%
Prior Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Effective interest rates					7.22%	7.08%
Prior Credit Agreement | LIBOR | Term Loan Facility A
Line Of Credit Facility [Line Items]
Margin rate					4.25%
Prior Credit Agreement | LIBOR | Term Loan Facility B
Line Of Credit Facility [Line Items]
Margin rate					5.25%
Prior Credit Agreement | LIBOR | Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Margin rate					3.75%
Prior Credit Agreement | LIBOR | Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Margin rate					4.25%
Interest Rate Swap Agreements
Line Of Credit Facility [Line Items]
Number of agreements held for maturity | Agreement				8	8
Derivative maturity month and year				2024-05
Interest Rate Swap Agreements | LIBOR
Line Of Credit Facility [Line Items]
Derivative, fixed interest rate				2.20%
Eight Interest Rate Swaps
Line Of Credit Facility [Line Items]
Derivative, notional amount					$ 600,000,000
Eight Interest Rate Swaps | Hedges
Line Of Credit Facility [Line Items]
Derivative, notional amount					$ 333,300,000
Description of interest rate swaps on derivatives					we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we de-designated these derivatives.

Debt - Summary of Debt, Net of

Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	$ 394,000	$ 496,275
Less: deferred loan costs and original issue discount	(13,496)	(29,569)
Total debt	380,504	466,706
Less: current portion		(7,456)
Total long-term debt	380,504	459,250
Term Loan A
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		124,035
Term Loan B
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	$ 394,000	$ 372,240

Debt - Summary of Effective Int

Debt - Summary of Effective Interest Rates Related to Continuing Operations for Term Loan A and Term Loan B (Details)	Dec. 31, 2021	Dec. 31, 2020
Prior Credit Agreement | Term Loan Facility A
Line Of Credit Facility [Line Items]
Effective interest rate per annum	6.58%	6.64%
Prior Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Effective interest rate per annum	7.22%	7.08%
Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Effective interest rate per annum	6.52%

Debt - Minimum Annual Principal

Debt - Minimum Annual Principal Payments and Repayments of the Revolving Advances (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Long Term Debt By Maturity [Abstract]
2023	$ 4,000
2024	4,000
2025	4,000
2026	4,000
2027 and thereafter	378,000
Total	$ 394,000	$ 496,275

Commitments and Contingencies -

Commitments and Contingencies - Additional Information - (Details) - USD ($)	Jan. 11, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 06, 2017
Loss Contingencies [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001	$ 0.001
Indemnification Agreement | Subsequent Event
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 25,000

Investment in Equity Securiti_2

Investment in Equity Securities - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 01, 2021	Jul. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021	Mar. 31, 2021
Schedule Of Equity Method Investments [Line Items]
Common stock, shares outstanding (in shares)			49,800,756	48,983,735
Carrying value of adjustable convertible equity right			$ 11,298	$ 9,930	$ 7,137
Business combination percentage of share converted into and paid in cash	2.40%
Sharecare equity security, Cost basis	$ 10,500
Average cost per share	$ 0.95
Number of common stock shares permitted to sell			120,000,000	120,000,000
Realized gain			$ 2,500
Unrealized gain			39,200
Realized and unrealized gains			41,700
Net income tax expense on sale of investment			0
Sharecare
Schedule Of Equity Method Investments [Line Items]
Reversed valuation allowance of deferred tax assets related to capital loss carryforwards			$ (10,600)
Period Between December 28, 2021 and March 27, 2022
Schedule Of Equity Method Investments [Line Items]
Number of common stock shares permitted to sell			750,000
Period Between March 28, 2022 and July 1, 2022
Schedule Of Equity Method Investments [Line Items]
Number of common stock shares permitted to sell			750,000
Legacy Sharecare
Schedule Of Equity Method Investments [Line Items]
Common stock, shares outstanding (in shares)				159,309		159,309	159,309
Legacy Sharecare | Other Assets
Schedule Of Equity Method Investments [Line Items]
Carrying value of adjustable convertible equity right				$ 10,800
Sharecare
Schedule Of Equity Method Investments [Line Items]
Common stock, shares outstanding (in shares)		11,079,331	11,079,331
Business combination, cash received		$ 2,700

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended			12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total impairment loss				$ 199,500,000		$ 377,100,000
Term Loan B
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument net fair value								$ 394,000,000
Debt instrument net carrying amount								394,000,000
Revolving Credit Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Line of credit								0
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents								$ 60,100,000
Nutrisystem, Inc.
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total impairment loss			$ 199,500,000	199,500,000	[1]	$ 377,100,000	[2]
Goodwill impairment loss				$ 90,200,000
Continuing Operations
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Goodwill impairment loss			0
Discontinued Operations | Nutrition
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Goodwill impairment loss	$ 24,000,000	$ 66,200,000
SilverSneakers | Continuing Operations | Tradename
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of intangibles			$ 0
[1]
[2]

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets:
Investment in equity securities	$ 49,746
Total assets	49,746
Liabilities:
Liabilities measured at fair value	15,643	$ 36,637
Level 1
Assets:
Investment in equity securities	49,746
Total assets	49,746
Level 2
Liabilities:
Liabilities measured at fair value	15,643	36,637
Interest Rate Swap Agreements | Derivatives Designated as Effective Hedging Instruments
Liabilities:
Liabilities measured at fair value	8,705	20,377
Interest Rate Swap Agreements | Derivatives Not Designated as Hedging Instruments
Liabilities:
Liabilities measured at fair value	6,938	16,260
Interest Rate Swap Agreements | Level 2 | Derivatives Designated as Effective Hedging Instruments
Liabilities:
Liabilities measured at fair value	8,705	20,377
Interest Rate Swap Agreements | Level 2 | Derivatives Not Designated as Hedging Instruments
Liabilities:
Liabilities measured at fair value	$ 6,938	$ 16,260

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details) - shares	Dec. 31, 2021	Jul. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares outstanding (in shares)	49,800,756		48,983,735
Sharecare
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares outstanding (in shares)	11,079,331	11,079,331
Other Income | Sharecare
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares outstanding (in shares)	11,079,331

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details) - Interest Rate Swap Agreements	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2020USD ($)	May 31, 2019Agreement	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)Agreement
Derivative [Line Items]
Number of interest rate swap agreements not qualified for hedge accounting treatment | Agreement				5
Number of interest rate swap agreements maintains hedging relationship | Agreement				3
Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Derivative [Line Items]
Number of amortizing interest rate swap agreements | Agreement		8
Derivative maturity month and year		2024-05
Derivative, fixed interest rate		2.20%
Derivative, notional amount				$ 333,300,000
Derivative amount reclassify pre-tax from accumulated OCI to interest expense within next 12 months				$ 6,600,000
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Number of de-designated amortizing interest rate swap agreements | Agreement				5
Recognized pre-tax loss on derivatives in discontinued operations			$ 14,300,000
Amount frozen that are previously deferred	$ 3,200,000
Floor interest rate of swaps				0.00%
Derivative, notional amount				$ 266,700,000

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) - Interest Rate Swap Agreements - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Liabilities:
Derivative liabilities	$ 8,705	$ 20,377
Derivatives Not Designated as Hedging Instruments
Liabilities:
Derivative liabilities	6,938	16,260
Current Portion of Long-term Liabilities | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Liabilities:
Current portion of long-term liabilities	5,911	8,205
Current Portion of Long-term Liabilities | Derivatives Not Designated as Hedging Instruments
Liabilities:
Current portion of long-term liabilities	4,714	6,548
Other Long-term Liabilities | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Liabilities:
Other long-term liabilities	2,794	12,172
Other Long-term Liabilities | Derivatives Not Designated as Hedging Instruments
Liabilities:
Other long-term liabilities	$ 2,224	$ 9,712

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Total other comprehensive (income) loss, gross of tax	$ 9,138	$ (5,298)	$ (12,091)
Interest Rate Swap Agreements
Derivative Instruments Gain Loss [Line Items]
Total other comprehensive (income) loss, gross of tax	(12,272)	7,116	16,238
Interest Rate Swap Agreements | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Derivative Instruments Gain Loss [Line Items]
(Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	(3,284)	33,247	16,930
Interest Rate Swap Agreements | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Loss related to de-designation of ineffective portion of derivatives, gross of tax effect		(14,336)
Interest Rate Swap Agreements | Interest Expense | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedges
Derivative Instruments Gain Loss [Line Items]
Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	(8,388)	(11,556)	$ (692)
Interest Rate Swap Agreements | Interest Expense | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect	$ (600)	$ (239)

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Schedule of Impact of Derivatives Not Designated as Hedges on Consolidated Statement of Operations (Details) - Derivatives Not Designated as Hedging Instruments - Interest Rate Swap Agreements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments Gain Loss [Line Items]
Impact of derivative instruments not designated as hedges	$ (2,027)	$ 14,801
Income From Discontinued Operations, Net of Income Tax
Derivative Instruments Gain Loss [Line Items]
Loss related to de-designation of ineffective portion of derivatives, gross of tax effect		14,336
Other (Income) Expense, Net
Derivative Instruments Gain Loss [Line Items]
Net (gain) loss related to ineffective portion of derivatives, gross of tax effect	(2,627)	226
Interest Expense
Derivative Instruments Gain Loss [Line Items]
Previously deferred loss related to de-designated swaps reclassified from accumulated OCI, gross of tax effect	$ 600	$ 239

Earnings (Loss) Per Share - Rec

Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended																12 Months Ended
		Dec. 31, 2021	[1]	Sep. 30, 2021		Jun. 30, 2021		Mar. 31, 2021		Dec. 31, 2020	[2]	Sep. 30, 2020		Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator [Abstract]
Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share		$ (25,038)		$ 103,699		$ 8,771		$ 19,944		$ 14,642		$ 16,750		$ 17,202		$ 8,275		$ 107,376	$ 56,869	$ 45,217
Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share		(308)		(932)		(414)		(808)		(26,260)		(59,168)		11,309		(206,381)		(2,462)	(280,500)	(332,038)
Net income (loss)		$ (25,346)		$ 102,767		$ 8,357		$ 19,136		$ (11,618)		$ (42,418)		$ 28,511		$ (198,106)		$ 104,914	$ (223,631)	$ (286,821)
Denominator [Abstract]
Shares used for basic income (loss) per share																		49,573	48,746	46,509
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Shares used for diluted income (loss) per share																		50,424	49,217	47,103
Earnings (loss) per share attributable to Tivity Health, Inc. - basic [Abstract]
Continuing operations (in dollars per share)		$ (0.50)	[3]	$ 2.09	[3]	$ 0.18	[3]	$ 0.41	[3]	$ 0.30	[3]	$ 0.34	[3]	$ 0.35	[3]	$ 0.17	[3]	$ 2.17	$ 1.17	$ 0.97
Discontinued operations (in dollars per share)		(0.01)	[3]	(0.02)	[3]	(0.01)	[3]	(0.02)	[3]	(0.54)	[3]	(1.21)	[3]	0.23	[3]	(4.25)	[3]	(0.05)	(5.75)	(7.14)
Net income (loss)	[4]	(0.51)	[3]	2.07	[3]	0.17	[3]	0.39	[3]	(0.24)	[3]	(0.87)	[3]	0.59	[3]	(4.08)	[3]	2.12	(4.59)	(6.17)
Earnings (loss) per share attributable to Tivity Health, Inc. - diluted [Abstract]
Continuing operations (in dollars per share)		(0.50)	[3]	2.06	[3]	0.17	[3]	0.40	[3]	0.29	[3]	0.34	[3]	0.35	[3]	0.17	[3]	2.13	1.16	0.96
Discontinued operations (in dollars per share)		(0.01)	[3]	(0.02)	[3]	(0.01)	[3]	(0.02)	[3]	(0.53)	[3]	(1.20)	[3]	0.23	[3]	(4.22)	[3]	(0.05)	(5.70)	(7.05)
Net income (loss)		$ (0.50)	[3],[4]	$ 2.04	[3],[4]	$ 0.17	[3],[4]	$ 0.38	[3],[4]	$ (0.23)	[3],[4]	$ (0.86)	[3],[4]	$ 0.58	[3],[4]	$ (4.05)	[3],[4]	$ 2.08	$ (4.54)	$ (6.09)
Non-Qualified Stock Options
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		60	29	90
Restricted Stock Units (RSUs)
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		538	412	489
Market Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		184	1
Performance-Based Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		69	29	15
Non-Qualified Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																		226	186	70
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																		20	242	192
Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																			26	102
Performance-Based Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																			24
[1]	Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses
[2]	Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.
[3]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[4]	Figures may not add due to rounding.

Accumulated OCI - Changes in Ac

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Changes in accumulated OCI, net of tax [Roll Forward]
Amounts reclassified from accumulated OCI, net of tax	$ 6,692	$ 19,458
Interest Rate Swap Agreements
Changes in accumulated OCI, net of tax [Roll Forward]
Balance	(17,389)	(12,091)
Other comprehensive income (loss) before reclassifications, net	2,446	(24,756)
Amounts reclassified from accumulated OCI, net of tax	6,692	19,458
Balance	$ (8,251)	$ (17,389)

Accumulated OCI - Changes in _2

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Other comprehensive income before reclassifications, tax	$ 838	$ 8,491
Amounts reclassified from accumulated OCI, tax	$ 2,296	$ 6,674

Accumulated OCI - Schedule of R

Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ 34,762	$ 43,477	$ 41,803
Income tax	(26,345)	(17,530)	(20,293)
Loss from discontinued operations	(2,462)	(280,500)	$ (332,038)
Total amounts reclassified from accumulated OCI	6,692	19,458
Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Total amounts reclassified from accumulated OCI	6,692	19,458
Reclassifications Out of Accumulate OCI
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Income tax	(2,296)	(3,012)
Loss from discontinued operations		10,675
Reclassifications Out of Accumulate OCI | Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ 8,988	$ 11,795

Other (Income) Expense, Net - S

Other (Income) Expense, Net - Summary of Other (Income) Expense, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Income And Expenses [Abstract]
Unrealized gain on investments in equity securities	$ (39,232)
Realized gain on investment in equity securities (Note 12)	(2,469)
Unrealized (gain) loss related to ineffective portion of derivatives (Note 14)	(2,627)	$ 226
Other (income) expense, net	$ (44,328)	$ 226

Segment Disclosures and Conce_2

Segment Disclosures and Concentrations of Risk - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021SegmentCustomer	Dec. 31, 2020SegmentCustomer
Revenue, Major Customer [Line Items]
Number of operating segments | Segment		1
Number of reportable segments | Segment	1	1
Percentage of long-lived assets and revenue from external customers in united states	100.00%	100.00%
Customer Concentration Risk | Revenues
Revenue, Major Customer [Line Items]
Number of largest individual customers | Customer	3	3
Customer Concentration Risk | Revenues | Minimum
Revenue, Major Customer [Line Items]
Percentage of concentration risk	40.00%	39.00%
Customer Concentration Risk | Accounts Receivable, Net
Revenue, Major Customer [Line Items]
Number of largest individual customers | Customer	2	2
Customer Concentration Risk | Accounts Receivable, Net | Minimum
Revenue, Major Customer [Line Items]
Percentage of concentration risk	10.00%	10.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer One
Revenue, Major Customer [Line Items]
Percentage of concentration risk	22.00%	26.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer Two
Revenue, Major Customer [Line Items]
Percentage of concentration risk	35.00%	33.00%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - USD ($)	Jan. 11, 2022	Dec. 31, 2021
Other Current Assets
Subsequent Event [Line Items]
Litigation settlement, amount		$ 25,000
Indemnification Agreement | Subsequent Event
Subsequent Event [Line Items]
Litigation settlement, amount	$ 25,000

Quarterly Financial Informati_3

Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended																12 Months Ended
		Dec. 31, 2021	[1]	Sep. 30, 2021		Jun. 30, 2021		Mar. 31, 2021		Dec. 31, 2020	[2]	Sep. 30, 2020		Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Revenues		$ 126,808		$ 126,289		$ 120,071		$ 108,085		$ 100,617		$ 95,481		$ 81,923		$ 159,692		$ 481,252	$ 437,714	$ 633,066
Gross margin		46,056		49,178		48,837		48,269		44,168		45,382		45,879		42,713
Income (loss) before income taxes		(15,424)		112,624		8,958		27,564		15,793		23,236		23,959		11,411		133,721	74,399	65,510
Income (loss) from continuing operations		(25,038)		103,699		8,771		19,944		14,642		16,750		17,202		8,275		107,376	56,869	45,217
Income (loss) from discontinued operations, net of income tax		(308)		(932)		(414)		(808)		(26,260)		(59,168)		11,309		(206,381)		(2,462)	(280,500)	(332,038)
Net income (loss)		$ (25,346)		$ 102,767		$ 8,357		$ 19,136		$ (11,618)		$ (42,418)		$ 28,511		$ (198,106)		$ 104,914	$ (223,631)	$ (286,821)
Earnings (loss) per share - basic:
Continuing operations		$ (0.50)	[3]	$ 2.09	[3]	$ 0.18	[3]	$ 0.41	[3]	$ 0.30	[3]	$ 0.34	[3]	$ 0.35	[3]	$ 0.17	[3]	$ 2.17	$ 1.17	$ 0.97
Discontinued operations		(0.01)	[3]	(0.02)	[3]	(0.01)	[3]	(0.02)	[3]	(0.54)	[3]	(1.21)	[3]	0.23	[3]	(4.25)	[3]	(0.05)	(5.75)	(7.14)
Net income (loss)	[4]	(0.51)	[3]	2.07	[3]	0.17	[3]	0.39	[3]	(0.24)	[3]	(0.87)	[3]	0.59	[3]	(4.08)	[3]	2.12	(4.59)	(6.17)
Earnings (loss) per share – diluted:
Continuing operations		(0.50)	[3]	2.06	[3]	0.17	[3]	0.40	[3]	0.29	[3]	0.34	[3]	0.35	[3]	0.17	[3]	2.13	1.16	0.96
Discontinued operations		(0.01)	[3]	(0.02)	[3]	(0.01)	[3]	(0.02)	[3]	(0.53)	[3]	(1.20)	[3]	0.23	[3]	(4.22)	[3]	(0.05)	(5.70)	(7.05)
Net income (loss)		$ (0.50)	[3],[4]	$ 2.04	[3],[4]	$ 0.17	[3],[4]	$ 0.38	[3],[4]	$ (0.23)	[3],[4]	$ (0.86)	[3],[4]	$ 0.58	[3],[4]	$ (4.05)	[3],[4]	$ 2.08	$ (4.54)	$ (6.09)
[1]	Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses
[2]	Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.
[3]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[4]	Figures may not add due to rounding.

Quarterly Financial Informati_4

Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($)	3 Months Ended										12 Months Ended
	Dec. 31, 2021		Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020		Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Unrealized loss											$ (39,200,000)
Net income tax benefit											26,345,000	$ 17,530,000	$ 20,293,000
Income (loss) from continuing operations	$ (25,038,000)	[1]	$ 103,699,000	$ 8,771,000	$ 19,944,000	$ 14,642,000	[2]	$ 16,750,000	$ 17,202,000	$ 8,275,000	107,376,000	$ 56,869,000	$ 45,217,000
Other (Income) Expense, Net
Unrealized loss	41,400,000
Unrealized gain related to de-designated swaps	1,900,000
Net income tax benefit	0
Selling, General and Administrative Expenses
Acquisition and integration costs						600,000
Transaction costs directly related to disposition of Nutrition	500,000										$ 500,000
Strategic Project Costs | Selling, General and Administrative Expenses
Income (loss) from continuing operations						2,300,000
CEO Transition Costs | Selling, General and Administrative Expenses
Income (loss) from continuing operations	$ (500,000)					$ 1,000,000
[1]	Loss from continuing operations for the fourth quarter of 2021 includes an unrealized loss of $41.4 million related to the change in fair value of the Sharecare Equity Security and an unrealized gain of $1.9 million related to the de-designated swaps, each of which was recorded to other (income) expense, net. The income tax benefit that would have otherwise resulted from the unrealized loss of $41.4 million was fully offset by income tax expense due to an increase in the valuation allowance on deferred tax assets related to capital loss carryforwards; therefore, there was no net income tax benefit associated with this loss. In addition, loss from continuing operations for the fourth quarter of 2021 includes a total of $0.5 million related to CEO transition costs, acquisition and integration costs, and project costs, which was primarily recorded to selling, general, and administrative expenses
[2]	Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.